Benjamin Bonavida

Benjamin Bonavida's AcademicInfluence.com Rankings

Benjamin Bonavida

Computer Science

#3547

World Rank

#3722

Historical Rank

Machine Learning

#449

World Rank

#455

Historical Rank

Artificial Intelligence

#646

World Rank

#657

Historical Rank

Database

#887

World Rank

#932

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Benjamin Bonavida's Degrees

PhD Computer Science Stanford University
Masters Computer Science Stanford University
Bachelors Computer Science University of California, Berkeley

Similar Degrees You Can Earn

Why Is Benjamin Bonavida Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Benjamin Bonavida's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Transcription factor YY1: structure, function, and therapeutic implications in cancer biology (2006) (678)
Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. (1997) (430)
Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic intervention (2014) (313)
Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. (2001) (304)
Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. (2001) (299)
Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention (2005) (279)
Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a population of CD16dimCD56- cells with low lytic activity. (1995) (243)
Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. (2003) (240)
Mechanism of cell-mediated cytotoxicity at the single cell level. I. Estimation of cytotoxic T lymphocyte frequency and relative lytic efficiency. (1979) (215)
Nitric oxide donors: novel cancer therapeutics (review). (2008) (213)
Inhibition of the Raf–MEK1/2–ERK1/2 Signaling Pathway, Bcl-xL Down-Regulation, and Chemosensitization of Non-Hodgkin’s Lymphoma B Cells by Rituximab (2004) (205)
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. (2011) (204)
Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. (1995) (198)
Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. (2012) (196)
‘Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions’ (2007) (196)
Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. (2005) (193)
Serum B‐cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival (2012) (188)
Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. (2004) (184)
Spontaneous cytotoxicity and tumor necrosis factor production by peripheral blood monocytes from AIDS patients. (1988) (184)
Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications (2015) (177)
Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-κB and inhibition of Bcl-xL expression (2004) (172)
Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. (2007) (164)
Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. (2004) (157)
Expression of transcription factor Yin Yang 1 in prostate cancer. (2005) (156)
Resveratrol and cancer: chemoprevention, apoptosis, and chemo-immunosensitizing activities. (2003) (156)
Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. I. Defective trigger on NK cells for NKCF production by target cells, and partial restoration by IL 2. (1986) (155)
Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction (2009) (155)
Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: Pivotal role of p38 MAPK in drug resistance (2004) (147)
Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics (review). (1999) (146)
Diphtheria toxin- and Pseudomonas A toxin-mediated apoptosis. ADP ribosylation of elongation factor-2 is required for DNA fragmentation and cell lysis and synergy with tumor necrosis factor-alpha. (1992) (144)
Mode of action of interferon-mediated modulation of natural killer cytotoxic activity: recruitment of pre-NK cells and enhanced kinetics of lysis. (1980) (142)
Studies on the mechanism of natural killer (NK) cell-mediated cytotoxicity (CMC). I. Release of cytotoxic factors specific for NK-sensitive target cells (NKCF) during co-culture of NK effector cells with NK target cells. (1982) (140)
Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis. (2007) (138)
Novel therapeutic applications of nitric oxide donors in cancer: roles in chemo- and immunosensitization to apoptosis and inhibition of metastases. (2008) (134)
Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. (1995) (133)
Selective lysis of NK-sensitive target cells by a soluble mediator released from murine spleen cells and human peripheral blood lymphocytes. (1981) (132)
Chemokine Monokine Induced by IFN-γ/CXC Chemokine Ligand 9 Stimulates T Lymphocyte Proliferation and Effector Cytokine Production1 (2004) (131)
Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1 (2007) (131)
The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-κB/Snail/RKIP/PTEN Circuit. (2010) (130)
Rituximab-Induced Inhibition of YY1 and Bcl-xL Expression in Ramos Non-Hodgkin’s Lymphoma Cell Line via Inhibition of NF-κB Activity: Role of YY1 and Bcl-xL in Fas Resistance and Chemoresistance, Respectively1 (2005) (129)
The activated NF-kappaB-Snail-RKIP circuitry in cancer regulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugs. (2009) (126)
Target-induced inactivation and cell death by apoptosis in a subset of human NK cells. (1996) (126)
Therapeutic potential of nitric oxide in cancer. (2006) (123)
Understanding tobacco smoke carcinogen NNK and lung tumorigenesis. (2006) (123)
Nitric Oxide Inhibits the Transcription Repressor Yin-Yang 1 Binding Activity at the Silencer Region of the Fas Promoter: A Pivotal Role for Nitric Oxide in the Up-Regulation of Fas Gene Expression in Human Tumor Cells1 (2001) (121)
Internucleosomal DNA cleavage precedes diphtheria toxin-induced cytolysis. Evidence that cell lysis is not a simple consequence of translation inhibition. (1989) (120)
Yin Yang 1 is associated with cancer stem cell transcription factors (SOX2, OCT4, BMI1) and clinical implication (2016) (119)
Dual role of NO donors in the reversal of tumor cell resistance and EMT: Downregulation of the NF-κB/Snail/YY1/RKIP circuitry. (2011) (115)
Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis (2005) (114)
Interleukin-6 induces G1 arrest through induction of p27(Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells. (1999) (113)
Cellular immunoadsorbents: a simplified technique for separation of lymphoid cell populations. (1974) (113)
X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-bi (2002) (111)
Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance. (2005) (109)
Pivotal role of endogenous TNF-alpha in the induction of functional inactivation and apoptosis in NK cells. (1997) (106)
Regulation of Tumor Cell Sensitivity to TRAIL-Induced Apoptosis by the Metastatic Suppressor Raf Kinase Inhibitor Protein via Yin Yang 1 Inhibition and Death Receptor 5 Up-Regulation (2007) (104)
Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. (2003) (102)
Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma. (1999) (102)
Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL‐mediated apoptosis of prostate cancer cells: Role of XIAP in resistance (2002) (99)
Mechanism of cell-mediated cytotoxicity at the single cell level. II. Evidence for first-order kinetics of T cell-mediated cytolysis and for heterogeneity of lytic rate. (1979) (98)
Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization. (2009) (97)
Nitric oxide sensitizes ovarian tumor cells to Fas-induced apoptosis. (1999) (97)
Mechanisms of nitric oxide-mediated inhibition of EMT in cancer (2010) (94)
Modification of gene products involved in resistance to apoptosis in metastatic colon cancer cells: roles of Fas, Apaf-1, NFkappaB, IAPs, Smac/DIABLO, and AIF. (2007) (93)
Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma. (2002) (92)
Inhibition of the transcription factor Yin Yang 1 activity by S-nitrosation. (2005) (91)
Nitric oxide-mediated sensitization of resistant tumor cells to apoptosis by chemo-immunotherapeutics☆ (2015) (91)
Human tear lysozyme. II. Quantitative determination with standard Schirmer strips. (1968) (90)
Prognostic significance of soluble Fas in the serum of patients with bladder cancer. (1998) (88)
Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular endothelial cells: a novel mechanism of tumor-induced vasculogenesis. (2009) (88)
Hypoxia Inducible Factor promotes murine allergic airway inflammation and is increased in asthma and rhinitis (2011) (86)
Expression of X-Linked Inhibitor of Apoptosis Protein Is a Strong Predictor of Human Prostate Cancer Recurrence (2007) (86)
NF-κB in the pathogenesis and treatment of multiple myeloma (2008) (85)
Studies on the mechanism of natural killer cytotoxicity. II. coculture of human PBL with NK-sensitive or resistant cell lines stimulates release of natural killer cytotoxic factors (NKCF) selectively cytotoxic to NK-sensitive target cells. (1983) (85)
Blocking signaling through the gp130 receptor chain by interleukin‐6 and oncostatin M inhibits PC‐3 cell growth and sensitizes the tumor cells to etoposide and cisplatin‐mediated cytotoxicity (1999) (85)
Doxorubicin sensitizes human bladder carcinoma cells to Fas‐mediated cytotoxicity (1997) (84)
Inhibition of Yin Yang 1-Dependent Repressor Activity of DR5 Transcription and Expression by the Novel Proteasome Inhibitor NPI-0052 Contributes to its TRAIL-Enhanced Apoptosis in Cancer Cells1 (2008) (83)
Overexpression of VEGF and TGF-beta1 mRNA in Pap smears correlates with progression of cervical intraepithelial neoplasia to cancer: implication of YY1 in cervical tumorigenesis and HPV infection. (2007) (83)
Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis (2007) (82)
Gene expression profile of metastatic colon cancer cells resistant to cisplatin-induced apoptosis. (2003) (81)
Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1. (2009) (80)
Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins. (1993) (79)
Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. II. Normal antibody-dependent cellular cytotoxicity (ADCC) mediated by effector cells defective in natural killer (NK) cytotoxicity. (1987) (78)
Target-induced anergy of natural killer cytotoxic function is restricted to the NK-target conjugate subset. (1995) (77)
Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil. (2002) (76)
The proteasome inhibitor CEP‐18770 enhances the anti‐myeloma activity of bortezomib and melphalan (2010) (74)
Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin. (2001) (73)
Mechanism of cell-mediated cytotoxicity at the single cell level. IV. Natural killing and antibody-dependent cellular cytotoxicity can be mediated by the same human effector cell as determined by the two-target conjugate assay. (1982) (73)
The novel role of Yin Yang 1 in the regulation of epithelial to mesenchymal transition in cancer via the dysregulated NF-κB/Snail/YY1/RKIP/PTEN Circuitry. (2011) (72)
Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab. (2000) (72)
Reversal of tumor resistance to apoptotic stimuli by alteration of membrane fluidity: therapeutic implications. (2007) (71)
Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis. (1997) (70)
Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c‐myc antisense oligonucleotide (1994) (68)
The participation of the Fas-mediated cytotoxic pathway by natural killer cells is tumor-cell-dependent (1997) (67)
Immunosensitization of Tumor Cells to Dendritic Cell-Activated Immune Responses with the Proteasome Inhibitor Bortezomib (PS-341, Velcade)1 (2006) (67)
Nitric oxide-mediated activity in anti-cancer photodynamic therapy. (2013) (67)
Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells. (1999) (65)
Rituximab-Mediated Cell Signaling and Chemo/Immuno-sensitization of Drug-Resistant B-NHL Is Independent of Its Fc Functions (2009) (65)
Nitric Oxide Disrupts H2O2-dependent Activation of Nuclear Factor κB (2001) (64)
Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity. (1997) (64)
Resistance of AIDS-associated Kaposi's sarcoma cells to Fas-mediated apoptosis. (1996) (64)
YY1 regulates cancer cell immune resistance by modulating PD-L1 expression. (2019) (64)
Involvement of the TNF-α autocrine–paracrine loop, via NF-κB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis (2006) (63)
Studies on the mechanism of natural killer cell-mediated cytotoxicity. IV. Interferon-induced inhibition of NK target cell susceptibility to lysis is due to a defect in their ability to stimulate release of natural killer cytotoxic factors (NKCF). (1983) (62)
TRAF6 activation in multiple myeloma: a potential therapeutic target. (2012) (62)
Evidence for several cell populations active in antibody dependent cellular cytotoxicity. (1973) (62)
Exosomes derived from cancerous and non-cancerous cells regulate the anti-tumor response in the tumor microenvironment (2018) (61)
Effect of platelet-activating factor on monocyte activation and production of tumor necrosis factor. (1989) (61)
Studies on the mechanism of natural killer cell-mediated cytotoxicity. VII. functional comparison of human natural killer cytotoxic factors with recombinant lymphotoxin and tumor necrosis factor. (1987) (61)
Actinomycin D and Gemcitabine Synergistically Sensitize Androgen-Independent Prostate Cancer Cells to Apo2L/TRAIL-Mediated Apoptosis (2001) (60)
Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis. (2001) (59)
Mechanism of Norepinephrine-Mediated Inhibition of Human NK Cytotoxic Functions: Inhibition of Cytokine Secretion, Target Binding, and Programming for Cytotoxicity (2002) (58)
A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: two complementary signals to overcome cross-resistance. (2002) (57)
Dual roles of nitric oxide in the regulation of tumor cell response and resistance to photodynamic therapy (2015) (57)
Raf Kinase Inhibitor Protein (RKIP) Blocks Signal Transducer and Activator of Transcription 3 (STAT3) Activation in Breast and Prostate Cancer (2014) (56)
Sensitization of AIDS-Kaposi's sarcoma cells to Apo-2 ligand-induced apoptosis by actinomycin D. (1999) (55)
CD40 Signaling Replaces CD4+ Lymphocytes and Its Blocking Prevents Chronic Rejection of Heart Transplants (2000) (55)
Correlation between the overexpression of Yin Yang 1 and the expression levels of miRNAs in Burkitt's lymphoma: A computational study (2015) (55)
Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor. (2006) (54)
Studies on the induction and expression of T cell-mediated immunity. VIII. Effector-target junctions and target cell membrane disruption during cytolysis. (1979) (54)
Differential regulation of human NK cell-associated gene expression following activation by IL-2, IFN-alpha and PMA/ionomycin. (1998) (53)
RKIP: A Key Regulator in Tumor Metastasis Initiation and Resistance to Apoptosis: Therapeutic Targeting and Impact (2018) (52)
The SJL/J T cell response to both spontaneous and transplantable syngeneic reticulum cell sarcoma is mediated predominantly by the V beta 17a+ T cell clonotype (1988) (52)
Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma (2004) (52)
Contribution of either YY1 or BclXL-induced inhibition by the NO-donor DETANONOate in the reversal of drug resistance, both in vitro and in vivo. YY1 and BclXL are overexpressed in prostate cancer. (2013) (51)
Synergistic effect of tumor necrosis factor-alpha- and diphtheria toxin-mediated cytotoxicity in sensitive and resistant human ovarian tumor cell lines. (1991) (51)
The single-cell assay in cell-mediated cytotoxicity. (1983) (50)
Inhibitory Effects of 17β-Estradiol and Progesterone on Ovarian Carcinoma Cell Proliferation: A Potential Role for Inducible Nitric Oxide Synthase (2001) (50)
Chemosensitization and immunosensitization of resistant cancer cells to apoptosis and inhibition of metastasis by the specific NF-kappaB inhibitor DHMEQ. (2009) (50)
YY1 Over-Expression in Human Brain Gliomas and Meningiomas Correlates with TGF-β1, IGF-1 and FGF-2 mRNA Levels (2009) (50)
Autoimmunity and aging: the age-related response of mice of a long-lived strain to trinitrophenylated syngeneic mouse red blood cells. (1976) (50)
Studies on the mechanism of natural killer cytotoxicity. III. Activation of NK cells by interferon augments the lytic activity of released natural killer cytotoxic factors (NKCF). (1983) (50)
Proteins in human tears. I. Immunoelectrophoretic patterns. (1969) (49)
Enhancement of host resistance against Salmonella typhimurium in mice fed a diet supplemented with yogurt or milks fermented with various Lactobacillus casei strains (1995) (49)
Immunomodulatory effect of tumor necrosis factor (1991) (49)
Sensitivity of resistant human tumor cell lines to tumor necrosis factor and adriamycin used in combination: correlation between down-regulation of tumor necrosis factor-messenger RNA induction and overcoming resistance. (1992) (48)
Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid (2007) (47)
Interferon-α activates cytotoxic function but inhibits interleukin-2-mediated proliferation and tumor necrosis factor-α secretion by immature human natural killer cells (2005) (47)
Regulation of B cell maturation and differentiation. I. Suppression of pokeweed mitogen-induced B cell differentiation by tumor necrosis factor (TNF). (1987) (47)
The NO TRAIL to YES TRAIL in cancer therapy (review). (2007) (47)
The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF-κB/Snail/RKIP/PTEN resistance loop in B-NHL cells: role in sensitization to TRAIL apoptosis. (2011) (46)
Role of CD8+ lymphocytes in chronic rejection of transplanted hearts. (2002) (46)
Combination treatment of malignant B cells using the anti-CD20 antibody rituximab and the anti-malarial artesunate. (2009) (46)
Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine. (2002) (45)
Expression of phosphorylated raf kinase inhibitor protein (pRKIP) is a predictor of lung cancer survival (2011) (45)
YAC-1 variant clones selected for resistance to natural killer cytotoxic factors are also resistant to natural killer cell-mediated cytotoxicity. (1983) (44)
CD8+ LYMPHOCYTES AUGMENT CHRONIC REJECTION IN A MHC CLASS II MISMATCHED MODEL (2001) (44)
In vitro and in vivo sensitization of SW620 metastatic colon cancer cells to CDDP-induced apoptosis by the nitric oxide donor DETANONOate: Involvement of AIF. (2009) (44)
Concanavalin A-mediated activation of antigen-primed lymphocytes into secondary cytotoxic lymphocytes (1977) (44)
Effect of altered membrane fluidity on NK cell-mediated cytotoxicity. I. Selective inhibition of the recognition or post recognition events in the cytolytic pathway of NK cells. (1985) (43)
Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis (2006) (43)
Prognostic significance of YY1 protein expression and mRNA levels by bioinformatics analysis in human cancers: a therapeutic target. (2015) (43)
2-Methoxyestradiol (2-ME) reduces the airway inflammation and remodeling in an experimental mouse model. (2008) (43)
The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo. (2011) (43)
Potentiation of cytotoxicity by combination of imatinib and chlorimipramine in glioma. (2008) (43)
Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-fas antibody-mediated cytotoxicity and apoptosis. (1996) (42)
Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis (2011) (42)
Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance. (2014) (42)
Specific Tear Prealbumin: a Unique Lachrymal Protein absent from Serum and other Secretions (1969) (42)
Interferon-alpha activates cytotoxic function but inhibits interleukin-2-mediated proliferation and tumor necrosis factor-alpha secretion by immature human natural killer cells. (1995) (41)
Involvement of the mitochondrion respiratory chain in the synergy achieved by treatment of human ovarian carcinoma cell lines with both tumor necrosis factor‐α and cis‐diamminedichloroplatinum (1996) (40)
Human tear lysozyme. 3. Preliminary study on lysozyme levels in subjects with smog eye irritation. (1968) (40)
Involvement of the TNF-alpha autocrine-paracrine loop, via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis. (2006) (40)
BRAF and RKIP are significantly decreased in cutaneous squamous cell carcinoma (2009) (39)
T and B lymphocytes: recognition and function (1979) (39)
Mechanism of cell-mediated cytotoxicity at the single cell level. III. Evidence that cytotoxic T lymphocytes lyse both antigen-specific and -nonspecific targets pretreated with lectins or periodate. (1981) (39)
Oncostatin M (OM) promotes the growth of DU 145 human prostate cancer cells, but not PC-3 or LNCaP, through the signaling of the OM specific receptor. (1999) (39)
A potential mechanism of rituximab-induced inhibition of tumor growth through its sensitization to tumor necrosis factor-related apoptosis-inducing ligand-expressing host cytotoxic cells (2011) (38)
HIF-1 expression is associated with CCL2 chemokine expression in airway inflammatory cells: implications in allergic airway inflammation (2012) (38)
Antigen-induced cyclophosphamide-resistant suppressor T cells inhibit the in vitro generation of cytotoxic cells from one-way mixed leukocyte reactions. (1977) (37)
Histamine receptor-bearing leukocytes (HRL). I. Detection of histamine receptor-bearing cells by rosette formation with histamine-coated erythrocytes. (1974) (37)
Repeated sub-optimal photodynamic treatments with pheophorbide a induce an epithelial mesenchymal transition in prostate cancer cells via nitric oxide. (2015) (37)
Activation of Natural Killer Cells by Probiotics. (2016) (37)
Antibody dependent cellular cytotoxicity: cytotoxicity mediated by non t-lymphocytes. (1974) (37)
HTLV-1 gene expression in adult T-cell leukemia cells elicits an NK cell response in vitro and correlates with cell rejection in SCID mice. (1996) (36)
Implication of TNF receptor-I-mediated extracellular signal-regulated kinases 1 and 2 (ERK1/2) activation in growth of AIDS-associated Kaposi's sarcoma cells: a possible role of a novel death domain protein MADD in TNF-alpha-induced ERK1/2 activation in Kaposi's sarcoma cells. (1999) (36)
Propagation of mouse cytotoxic clones with characteristics of natural killer (NK) cells. (1982) (36)
Specific enhancement of tumor growth and depression of cell-mediated immunity following sensitization to soluble tumor antigens. (1976) (36)
LECTIN‐DEPENDENT CELLULAR CYTOTOXICITY IN MAN (1977) (35)
Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction. (2011) (35)
Overcoming cis‐diamminedichloroplatinum (II) resistance of human ovarian tumor cells by combination treatment with cis‐diamminedichloroplatinum (II) and tumor necrosis factor–alpha (1993) (35)
Studies on the mechanism of natural killer cell-mediated cytotoxicity. V. Lack of NK specificity at the level of induction of natural killer cytotoxic factors in cultures of human, murine, or rat effector cells stimulated with mycoplasma-free cell lines. (1984) (35)
Studies on the lethal hit stage of natural killer cell-mediated cytotoxicity. I. Both phorbol ester and ionophore are required for release of natural killer cytotoxic factors (NKCF), suggesting a role for protein kinase C activity. (1986) (35)
Concomitant killing in vitro of both gp120-coated CD4+ peripheral T lymphocytes and natural killer cells in the antibody-dependent cellular cytotoxicity (ADCC) system. (1997) (34)
Studies of the induction and expression of T cell mediated immunity. VI. Heterogeneity of lytic efficiency exhibited by isolated cytotoxic T lymphocytes prepared from highly enriched populations of effector-target conjugates. (1977) (34)
Nitric Oxide-Mediated Enhancement and Reversal of Resistance of Anticancer Therapies (2019) (34)
Histamine-receptor leucocytes (HRL). Organ and lymphoid subpopulation distribution in man. (1977) (34)
Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II). (1998) (34)
Antibody-dependent cellular cytotoxicity against HIV-coated target cells by peripheral blood monocytes from HIV seropositive asymptomatic patients. (1990) (34)
Inverse correlation between the metastasis suppressor RKIP and the metastasis inducer YY1: Contrasting roles in the regulation of chemo/immuno-resistance in cancer. (2017) (34)
Viral infection and cancer: the NF-kappaB/Snail/RKIP loop regulates target cell sensitivity to apoptosis by cytotoxic lymphocytes. (2010) (34)
Crosstalks between Raf-kinase inhibitor protein and cancer stem cell transcription factors (Oct4, KLF4, Sox2, Nanog) (2017) (33)
Studies on the induction and expression of T cell-mediated immunity. XI. Inhibition of the "lethal hit" in T cell-mediated cytotoxicity by heterologous rat antiserum made against alloimmune cytotoxic T lymphocytes. (1979) (33)
Purification and characterization of cytolytic and noncytolytic human natural killer cell subsets. (1990) (33)
Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent. (2007) (33)
Mechanism of cell-mediated cytotoxicity at the single cell level. VIII. Kinetics of lysis of target cells bound by more than one cytotoxic T lymphocyte. (1979) (32)
LAGlambda-1: a clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma. (2006) (32)
RKIP-mediated chemo-immunosensitization of resistant cancer cells via disruption of the NF-κB/Snail/YY1/RKIP resistance-driver loop. (2014) (32)
Role of YY1 in the pathogenesis of prostate cancer and correlation with bioinformatic data sets of gene expression (2014) (32)
Calcium-independent pathway of tumor necrosis factor-mediated lysis of target cells. (1989) (31)
Platelet-activating factor and the cytokine network in inflammatory processes (1995) (31)
Pleiotrophin is highly expressed by myeloma cells and promotes myeloma tumor growth. (2007) (31)
Studies on the induction and expression of T cell-mediated immunity. I. Blocking of cell-mediated cytolysis by membrane antigens. (1974) (31)
Tumor necrosis factor/cachectin and related cytokines (1988) (30)
Immune functions characteristic of SJL/J mice and their association with age and spontaneous reticulum cell sarcoma. (1976) (29)
An Antibody-based Multifaceted Approach Targeting the Human Transferrin Receptor for the Treatment of B-cell Malignancies (2011) (29)
Structural basis for immune recognition of lysozymes. I. Effect of cyanogen bromide on hen egg-white lysozyme. (1969) (29)
Targeting the Overexpressed YY1 in Cancer Inhibits EMT and Metastasis. (2017) (29)
Tumor necrosis factor : structure, mechanism of action, role in disease and therapy (1990) (29)
Differential secretion of TNF-α and IFN-γ by human peripheral blood-derived NK subsets and association with functional maturation (2005) (29)
Differential secretion of TNF-alpha and IFN-gamma by human peripheral blood-derived NK subsets and association with functional maturation. (1996) (28)
Chemoimmunosensitization of the T24 human bladder cancer line to Fas-mediated cytotoxicity and apoptosis by cisplatin and 5-fluorouracil. (1999) (28)
Regulated interleukin-10 expression prevents chronic rejection of transplanted hearts. (2003) (28)
Peripheral blood monocytes derived from HIV+ individuals mediate antibody-dependent cellular cytotoxicity (ADCC). (1990) (27)
Inhibition of Epithelial-to-Mesenchymal Transition (EMT) in Cancer by Nitric Oxide: Pivotal Roles of Nitrosylation of NF-κB, YY1 and Snail. (2012) (27)
Tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) for treatment of prostate cancer: first results and review of the literature (1999) (27)
MHC-Class I antigens regulate both the function and the survival of human peripheral blood NK cells: role of endogenously secreted TNF-alpha. (2000) (27)
Activation of the human immature natural killer cell subset by IL-12 and its regulation by endogenous TNF-α and IFN-γ secretion (1994) (27)
Quantitative structure-activity relationships of phenolic compounds causing apoptosis. (2003) (27)
Nitric oxide (NO) and cancer (2010) (27)
Prognostic significance of a combination of soluble Fas and soluble Fas ligand in the serum of patients with Ta bladder cancer. (2002) (26)
Antibody-mediated in vivo suppression of EL4 leukemia in a syngeneic host. (1974) (26)
Expression of hybrid Ia molecules on the cell surface of reticulum cell sarcomas that are undetectable on host SJL/J lymphocytes (1981) (26)
Molecular Interactions in T‐Cell‐Mediated Cytotoxicity (1983) (26)
Mechanism of activation of human peripheral blood NK cells at the single cell level by Echinacea water soluble extracts: recruitment of lymphocyte-target conjugates and killer cells and activation of programming for lysis. (2003) (25)
The NF-κB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs (2008) (25)
Roles Each of Snail, Yin Yang 1 and RKIP in the Regulation of Tumor Cells Chemo-immuno-resistance to Apoptosis. (2013) (25)
Human tear lysozyme. I. Purification, physicochemical, and immunochemical characterization. (1967) (25)
Mechanism of inhibition of human natural killer activity by ultraviolet radiation. (1984) (25)
Studies on the induction and expression of T cell-mediated immunity. II. Antiserum blocking of cell-mediated cytolysis. (1974) (25)
Sensitization of immunoresistant prostate carcinoma cell lines to Fas/Fas ligand‐mediated killing by cytotoxic lymphocytes: Independence of de novo protein synthesis (1999) (25)
Studies on the induction and expression of T cell-mediated immunity. XII. The concomitant loss and recovery of membrane-associated Lyt-2 antigens, lymphocyte-target cell binding, and the antigen-specific and -nonspecific cytotoxic activity of alloimmune T lymphocytes after treatment with trypsin. (1981) (24)
Natural killer cell anergy to cytokine stimulants in a subgroup of patients with heart failure: relationship to norepinephrine. (1995) (24)
P38 MAPK expression and activation predicts failure of response to CHOP in patients with Diffuse Large B-Cell Lymphoma (2015) (24)
Immunosensitization of Melanoma Tumor Cells to Non-MHC Fas-Mediated Killing by MART-1-Specific CTL Cultures1 (2001) (24)
Cellular immunoadsorbents. An improved technique for specific depletion of cytotoxic (T) lymphoid cells. (1974) (24)
Prognostic significance of second mitochondria-derived activator of caspase (Smac/DIABLO) expression in bladder cancer and target for therapy. (2010) (23)
Capacity of tumor necrosis factor to bind and penetrate membranes is pH-dependent. (1988) (23)
Sequential appearance of antibodies directed against different antigenic determinants of hen egg‐white lysozyme (1971) (23)
Pivotal role of endogenous TNF-alpha in the IL-2-driven activation and proliferation of the functionally immature NK free subset. (1993) (23)
Mechanism of NK activation by OK-432 (Streptococcus pyogenes). I. Spontaneous release of NKCF and augmentation of NKCF production following stimulation with NK target cells. (1986) (23)
Overexpression of RKIP and its cross-talk with several regulatory gene products in multiple myeloma (2017) (23)
Analysis of lymphocyte-target conjugates by flow cytometry. I. Discrimination between killer and non-killer lymphocytes bound to targets and sorting of conjugates containing one or multiple lymphocytes. (1986) (22)
Natural killer cell subsets: maturation, differentiation and regulation. (1993) (22)
Effects of platelet-activating factor on peripheral blood monocytes: induction and priming for TNF secretion. (1990) (22)
Effect of altered membrane structure on NK cell-mediated cytotoxicity. III. Decreased susceptibility to natural killer cytotoxic factor (NKCF) and suppression of NKCF release by membrane rigidification. (1987) (22)
Overcoming TNF-α and Drug Resistance of Human Renal Cell Carcinoma Cells by Treatment with Pentoxifylline in Combination with TNF-α or Drugs: The Role of TNF-α mRNA Downregulation in Tumor Cell Sensitization (1994) (22)
Overexpression of Yin Yang 1 in bone marrow-derived human multiple myeloma and its clinical significance. (2014) (21)
Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance (2016) (21)
Expression of KLF4 is a predictive marker for survival in pediatric Burkitt lymphoma (2014) (21)
Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes. (2003) (20)
Frequency determination of killer cells by a single-cell cytotoxic assay. (1983) (20)
Transplantation of allogeneic lymphoid cells specifically depleted of graft versus host reactive cells (1974) (20)
Nitric Oxide Donors Are a New Class of Anti-cancer Therapeutics for the Reversal of Resistance and Inhibition of Metastasis (2010) (20)
Both HPV and carcinogen contribute to the development of resistance to apoptosis during oral carcinogenesis. (2000) (20)
Activation of human peripheral-blood-derived monocytes by cis-diamminedichloroplatinum: enhanced tumoricidal activity and secretion of tumor necrosis factor-alpha. (1992) (20)
Lethal iron deprivation induced by non-neutralizing antibodies targeting transferrin receptor 1 in malignant B cells (2011) (20)
A single cell marker of active NK cytotoxicity: only a fraction of target binding lymphocytes are killer cells. (1980) (20)
Higher expression levels of 14-3-3sigma in ductal carcinoma in situ of the breast predict poorer outcome. (2009) (19)
Preferential induction of serum blocking activity and enhancement of skin allograft by soluble alloantigen. (1974) (19)
Sensitizing activities of nitric oxide donors for cancer resistance to anticancer therapeutic drugs. (2020) (19)
Enhanced susceptibility of cis‐diamminedichloroplatinum‐treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells (1993) (19)
The SJL/J spontaneous reticulum cell sarcoma: new insights in the fields of neoantigens, host-tumor interactions, and regulation of tumor growth. (1983) (19)
Linking Autophagy and the Dysregulated NFκB/ SNAIL/YY1/RKIP/PTEN Loop in Cancer: Therapeutic Implications. (2018) (19)
Detection of soluble tumor-associated antigens in serum of tumor-bearing rats and their immunological role in vivo. (1977) (19)
Dysregulation of the cell survival/anti-apoptotic NF-kappaB pathway by the novel humanized BM-ca anti-CD20 mAb: implication in chemosensitization. (2009) (19)
Lysis of uninfected HIV-1 gp120-coated peripheral blood-derived T lymphocytes by monocyte-mediated antibody-dependent cellular cytotoxicity. (1995) (18)
Sensitization of cancer cells for chemo/immuno/radio-therapy (2008) (18)
Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells. (1990) (18)
Inhibitory effects of 17beta-estradiol and progesterone on ovarian carcinoma cell proliferation: a potential role for inducible nitric oxide synthase. (2001) (18)
Serum pleiotrophin levels are elevated in multiple myeloma patients and correlate with disease status (2006) (18)
Galiximab Signals B-NHL Cells and Inhibits the Activities of NF-κB–Induced YY1- and Snail-Resistant Factors: Mechanism of Sensitization to Apoptosis by Chemoimmunotherapeutic Drugs (2012) (18)
Dexamethasone enhances expression of membrane and soluble interleukin-6 receptors by prostate carcinoma cell lines. (1998) (18)
Studies on the induction and expression of T cell-mediated immunity. XV. Role of non-MHC papain-sensitive target structures and Lyt-2 antigens in allogeneic and xenogeneic lectin-dependent cellular cytotoxicity (LDCC). (1974) (18)
Antibodies to transfer RNA obtained with covalently linked tRNA conjugates. (1970) (18)
Therapeutic YY1 Inhibitors in Cancer: ALL in ONE. (2017) (17)
Studies on the induction and expression of T cell-mediated immunity. IV. Non-overlapping populations of alloimmune cytotoxic lymphocytes with specificity for tumor-associated antigens and transplantation antigens. (1975) (17)
Nitric Oxide and Cancer: Pathogenesis and Therapy (2015) (17)
Effect of platelet-activating factor (PAF) on monocyte activation and production of tumor necrosis factor (TNF) (1988) (17)
Tumor necrosis factor : structure-function relationship and clinical application (1992) (17)
Inhibition of NF-kappaB and Akt pathways by an antibody-avidin fusion protein sensitizes malignant B-cells to cisplatin-induced apoptosis. (2010) (17)
Inosine-coated bacteriophage T 4 . (1971) (17)
Cytotoxic and cytostatic effects of the streptococcal preparation OK‐432 and its subcellular fractions on human ovarian tumor cells (1989) (17)
Enhanced susceptibility of cis-diamminedichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells. (1993) (17)
QSAR of apoptosis induction in various cancer cells. (2003) (17)
Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy (2013) (16)
Direct estimation of frequency of cytotoxic T lymphocytes by a modified plaque assay (1976) (16)
A novel angiogenesis model for screening anti-angiogenic compounds: the chorioallantoic membrane/feather bud assay. (2010) (16)
Initiation and characterization of cultured tumor lines from spontaneous reticulum cell sarcoma of SJL/J mice. (1977) (16)
Nitric oxide disrupts H2O2-dependent activation of nuclear factor kappa B. Role in sensitization of human tumor cells to tumor necrosis factor-alpha -induced cytotoxicity. (2001) (16)
Unique Pattern of Overexpression of Raf-1 Kinase Inhibitory Protein in Its Inactivated Phosphorylated Form in Human Multiple Myeloma. (2011) (16)
Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma. (2005) (15)
Synergy is documented in vitro with low‐dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells (1991) (15)
Regulation of Ia+ reticulum cell sarcoma (RCS) growth in syngeneic SJL/J mice. I. Inhibition of tumor growth by passive administration of L3T4 monoclonal antibody before or after tumor inoculation. (1987) (15)
Respectively Resistance and Chemoresistance , in FasLActivity : Role of YY 1 and Bcl-x B κ Lymphoma Cell Line via Inhibition of NF-Expression in Ramos Non-Hodgkin ' sLBcl-x Rituximab-Induced Inhibition of YY 1 and Benjamin Bonavida (2005) (15)
Immune response of New Zealand mice to trinitrophenylated syngeneic mouse red cells (1976) (14)
Rabbit tear proteins. I. Detection and quantitation of lysozyme in nonstimulated tears. (1968) (14)
Overexpression of Yin Yang 1 in the pathogenesis of human hematopoietic malignancies. (2011) (14)
Specific antibodies to dinucleotides and trinucleotides. (1972) (13)
T-cell membrane antigens associated with cytotoxic function. (1982) (13)
Activation of the human immature natural killer cell subset by IL-12 and its regulation by endogenous TNF-alpha and IFN-gamma secretion. (1994) (13)
Enhanced Susceptibility of c‐myc Antisense Oligonucleotide‐Treated Human Renal Cell Carcinoma Cells to Lysis by Peripheral Blood Lymphocytes (1995) (13)
Modulation of the immune response toward allografts in vivo. I. Selective suppression of the development of cell-mediated immunity by soluble alloantigens. (1974) (13)
Frequency determination of K cells by a single cell cytotoxic assay. (1980) (13)
Low circulating serum levels of second mitochondria-derived activator of caspase (Smac/DIABLO) in patients with bladder cancer (2012) (13)
Inhibition of Constitutive STAT 3 Activity Sensitizes Resistant Non-Hodgkin ’ s Lymphoma and Multiple Myeloma to Chemotherapeutic Drug-mediated Apoptosis 1 (2003) (13)
Overcoming TNF-alpha and drug resistance of human renal cell carcinoma cells by treatment with pentoxifylline in combination with TNF-alpha or drugs: the role of TNF-alpha mRNA downregulation in tumor cell sensitization. (1994) (13)
Regulation of T Cells in Cancer by Nitric Oxide (2021) (12)
Oral Dosing of the Novel Proteasome Inhibitor CEP-18770 Shows Marked Anti-Myeloma Effects in SCID-Hu Models of Multiple Myeloma. (2009) (12)
Sensitivity of human renal cell carcinoma lines to TNF, adriamycin, and combination: role of TNF mRNA induction in overcoming resistance. (1993) (12)
INAPPROPRIATE ALLOANTIGEN‐LIKE SPECIFICITIES DETECTED ON SPONTANEOUS AND TRANSPLANTABLE RETICULUM CELL SARCOMAS OF SJL/J MICE (1980) (12)
Overcoming tnf-alpha and cddp resistance of a human ovarian-cancer cell-line (c30) by treatment with buthionine sulfoximine in combination with tnf-alpha and or cddp. (1993) (12)
Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy (2015) (12)
Sensitivity of drug-resistant human ovarian tumor cell lines to combined effects of tumor necrosis factor (TNF-alpha) and doxorubicin: failure of the combination to modulate the MDR phenotype. (1993) (12)
A sensitive immunoassay for human lysozyme in biological fluids. (1971) (12)
Activation of human peripheral blood-derived monocytes by OK-432 (Streptococcus pyogenes): augmented cytotoxicity and secretion of TNF and synergy with rIFN-gamma. (1989) (12)
What signals are generated by anti-CD20 antibody therapy? (2006) (11)
Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis (2007) (11)
Autoreactive antibody-forming cells directed against thymocytes and thymus-derived lymphocytes. (1978) (11)
Irreversible cancer cell-induced functional anergy and apoptosis in resting and activated NK cells. (1999) (11)
Ricin-mediated cell-lysis and apoptosis of drug sensitive and resistant tumor-cells. (1993) (11)
Enzyme-linked immunosorbent assay for HLA determination on fresh and dried lymphocytes. (1983) (11)
The in vivo depletion of V beta 17a+ T cells results in the inhibition of reticulum cell sarcoma growth in SJL/J mice. Evidence for the use of anticlonotypic antibody therapy in the control of malignancy. (1989) (11)
Sensitization of Rituximab-Resistant Ramos RR1 and Daudi RR1 Clones to Various Chemotherapeutic Drugs by a Novel Nuclear Factor-κB Activation Inhibitor. (2004) (10)
Cytotoxic activity of synthetic aza alkyl lysophospholipids against drug sensitive and drug resistant human tumor cell lines. (1991) (10)
Inappropriate alloantigen-like specificities detected on reticulum cell sarcomas of SJL/J mice: characterization and biologic role. (1980) (10)
Prolonged asymptomatic states in HIV-seropositive persons with 50 CD4+ T-cells/mm3: preliminary psychoimmunologic findings. (1993) (10)
Structural basis for immune recognition of lysozymes. II. Reactive but non‐immunogenic epitopes (1971) (10)
Specific lymphocyte-target cell conjugate formation between tumor-specific helper T-cell hybridomas and IA-bearing RCS tumors and IE-bearing allogeneic cells. I. Role of Ia and both L3T4 and LFA-1 antigens in recognition/binding. (1986) (10)
Prognostic significance of a combination of thymidylate synthase and dihydropyrimidine dehydrogenase activities in grades 1 and 2 superficial bladder cancer. (2002) (10)
A New Linkage between the Tumor Suppressor RKIP and Autophagy: Targeted Therapeutics. (2018) (10)
Effect of altered membrane structure on NK cell-mediated cytotoxicity. II. Conversion of NK-resistant tumor cells into NK-sensitive targets upon fusion with liposomes containing NK-sensitive membranes. (1986) (10)
Mechanism of cell-mediated cytotoxicity at the single-cell level. VII. Trigger of the lethal hit event is distinct for NK/K and LDCC effector cells as measured in the two-target conjugate assay. (1984) (10)
Heterogenous populations of cytotoxic cells in the peritoneal cavity of BALB/c mice immunized with allogeneic EL4 leukemia cells. (1974) (10)
Characterization of antibody-mediated inhibition of natural killer (NK) cytotoxicity: evidence for blocking of both recognition and lethal hit stages of cytolysis. (1983) (9)
Arsenic Trioxide Shows Synergistic Anti-Myeloma Effects When Combined with Bortezomib and Melphalan In Vitro and Helps Overcome Resistance of Multiple Myeloma Cells to These Treatments in Vivo. (2004) (9)
Cell-mediated immune resistance in cancer (2020) (9)
Multistage model of natural killer cell-mediated cytotoxicity involving NKCF as soluble cytotoxic mediators. (1987) (9)
The involvement of platelet-activating factor (PAF)-induced monocyte activation and tumor necrosis factor (TNF) production in shock. (1989) (9)
Structural basis for immune recognition of lysozymes. IV. Immunologically active peptide obtained by the action of cyanogen bromide on human lysozyme. (1971) (9)
Ascorbic Acid Overcomes Drug Resistance in Myeloma and Significantly Increases the Anti-Myeloma Effects of both Arsenic Trioxide and Melphalan in Vitro and in Vivo. (2004) (9)
Assessment of cell-mediated cytotoxicity. (1980) (9)
Regulation Of Cell Death Apoptotic Pathways By Nitric Oxide In Cancer: Reversal Of Drug/Immune Resistance. (2015) (9)
Cross-reactivity of some rabbit anti-human lysozyme sera with gallinaceous lysozymes. (1971) (9)
A "nonidiotypic" inhibition of influenza-immune H-2-restricted CTL by an anti-T cell serum. (1980) (9)
Biochemical characterization of natural killer cytotoxic factors. (1985) (9)
NATURAL KILLER CELLS ARE DISTINCT FROM LECTIN-DEPENDENT EFFECTOR CELLS IN MAN AS DETERMINED BY THE TWO-TARGET CONJUGATE SINGLE CELL ASSAY (1982) (8)
Mechanism of cell-mediated cytotoxicity at the single cell level. V. The importance of target cell structure in cytotoxic T lymphocyte-mediated antigen nonspecific lectin-dependent cellular cytotoxicity. (1982) (8)
Enzyme-linked immunosorbent assay for determination of HLA: gene dose effect. (2008) (8)
TNF as immunomodulatory agent. (1992) (8)
Inhibition of tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β) secretion but not IL-6 from activated human peripheral blood monocytes by a new synthetic demethylpodophyllotoxin derivative (1994) (8)
Studies on the induction and expression of T cell-mediated immunity. VII. Inactivation of autologous cytotoxic T lymphocytes when used as both effectors and targets in a lectin-dependent cellular cytotoxic reaction. (1977) (8)
Molecular pathogenesis of AIDS-associated Kaposi's sarcoma: growth and apoptosis. (2000) (8)
Tears as carriers of antibodies. II. Charge heterogeneity of IgG antibodies in rabbit tears. (1968) (8)
Role of natural killer cytotoxic factors in the mechanism of target-cell killing by natural killer cells (2004) (8)
Cellular and Molecular Characterization of Rituximab-Resistant CD20+ NHL Ramos (Ramos RR1) and Daudi (Daudi RR1) Clones: Development of Cross-Resistance to Cytotoxic Stimuli. (2004) (8)
NK cell phenotypic and functional heterogeneities and molecular mechanisms of cytotoxicity. (2014) (8)
Anti-Myeloma Activity by the Combination of the JAK2 Inhibitor Ruxolitinib with Lenalidomide and Corticosteroids (2014) (8)
Death receptor 5 expression is inversely correlated with prostate cancer progression (2017) (8)
Studies on the induction and expression of T cell-mediated immunity. 3. Amplification by papain of the generation of cytotoxic lymphocytes to allogeneic cells. (1974) (8)
Preface: antibody therapies for cancer (2007) (8)
Use of a self-generating percoll gradient and single cell cytotoxicity assay to identify tumor-lytic properties of inflammatory neutrophils. (1985) (8)
Rituximab-Mediated Inhibition of the Constitutive NIK/IKK/IκB/NF-κB Signaling Pathway in Non-Hodgkin’s Lymphoma (NHL) B-Cell Lines: Role in Chemo-Sensitization. (2004) (8)
Sensitivity of fresh and cultured ovarian tumor cells to tumor necrosis factor, interferon-alpha 2, and OK-432 (2004) (7)
Increased M2 Macrophages in Multiple Myeloma Patients with Progressive Disease and Down-Regulated Polarization with the JAK2 Inhibitor Ruxolitinib (2014) (7)
Hierarchy of Tumor Cell Sensitivity and Resistance to Cytolysis by TNF, Cytotoxic Cells, Bacterial Toxins, and Cytotoxic Drugs (1990) (7)
Immunologic control of ovarian cancer. (1988) (7)
Killer cell recruitment and renewal capacity of purified cytolytic and noncytolytic human peripheral blood natural killer cell subsets. (1993) (7)
Death receptor 5 expression is inversely correlated with prostate cancer progression (2014) (7)
Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine (2013) (7)
Antibody-dependent cellular cytotoxicity (ADCC)-mediated destruction of human immunodeficiency virus (HIV)-coated CD4+ T lymphocytes by acquired immunodeficiency syndrome (AIDS) effector cells (1988) (7)
Long non-coding RNAs (lncRNAs) signaling in cancer chemoresistance: From prediction to druggability. (2022) (7)
Lysis of NK target cells by soluble cytotoxic factor(s) and inhibition by a xenoantiserum directed against cytotoxic cells. (1981) (7)
Cycloheximide-induced modulation of TNF-mediated cytotoxicity in sensitive and resistant ovarian tumor cells (2008) (7)
Cyclophosphamide-sensitive and cyclophosphamide-resistant suppressor cells in the immune response to alloantigens. (1979) (7)
Detection and characterization of lymphocytes bearing receptors for peanut agglutinin by a specific rosetting technique. (1981) (7)
Can we develop biomarkers that predict response of cancer patients to immunotherapy? (2005) (7)
Preferential Induction of TNF-α and IL-1β and Inhibition of IL-10 Secretion by Human Peripheral Blood Monocytes by Synthetic Aza–Alkyl Lysophospholipids (1999) (7)
The Novel Proteasome Inhibitor CEP-18770 Inhibits Myeloma Tumor Growth In Vitro and In Vivo and Enhances the Anti-MM Effects of Melphalan (2008) (7)
Nucleoside-coated bacteriophage T4: a method for the detection and characterization of anti-nucleoside antibodies. (1972) (7)
Immunological unresponsiveness induced in adult mice to synthetic polypeptides built on multichain polyproline and multichain polyalanine. (1974) (7)
Expression of inappropriate H-2 antigens on SJL reticulum cell tumors. (1979) (7)
A comparative study of intravenous versus intralymphatic interleukin-2, with assessment of effects of interleukin-2 on both peripheral blood and thoracic-duct lymph. (1994) (7)
Inhibition of IA positive reticulum cell sarcoma tumor cell growth in syngeneic SJL/J mice by passive administration of monoclonal anti-IA antibody. (1986) (6)
Serological demonstration of an allogeneic Ia.7 antigen on the cell surface of SJL/J-derived reticulum cell sarcomas. (1983) (6)
Studies on the induction and expression of T cell-mediated immunity. XIV. Antigen-nonspecific oxidation-dependent cellular cytotoxicity (ODCC) mediated by sodium periodate oxidation of cytotoxic T lymphocytes. (1983) (6)
Mechanism of cell-mediated cytotoxicity at the single cell level. VI. Direct assessment of the cytotoxic potential of human peripheral blood non-lytic effector-target cell conjugates. (1984) (6)
Qualitative and quantitative analysis of subpopulations of cytotoxic effector cells by flow cytometry. (1994) (6)
Mapping of SJL/J reticulum cell sarcoma tumor-associated Ia antigens by T cell hybridomas: characterization of tumor-specific and shared epitopes detected on IE+ allogeneic cells. (1986) (6)
Significance of cytotoxic activity of peripheral blood lymphocytes against autologous tumor cells in patients with bladder cancer. (1996) (6)
Blocking activity induced by solubilized alloantigens. (1974) (6)
Strain-dependent differences in susceptibility of mice to experimental pyelonephritis. (1985) (6)
Dose-response effects of 4-hydroperoxycyclophosphamide on human T and B cell function in vitro. (1985) (6)
Prolonged Asymptomatic States in HIV‐Seropositive Persons with Fewer Than 50 CD4+ T Cells per MM3 Psychoneuroimmunologic Findings (1994) (6)
1 Polycomb protein EZH 2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer (2012) (6)
Studies on the mechanism of natural killer cell-mediated cytotoxicity. VI. Characterization of human, rat, and murine natural killer cytotoxic factors. (1985) (6)
Circumvention of tumor cell escape following specific immunotherapy. (2000) (5)
Anti-inosine antibodies of different specificity produced by immunization with two immunogens. (1972) (5)
Opsonization of alloreactive Ly-1+ T cells by antigen-antibody complexes containing free I-A determinants. (1979) (5)
Studies on the induction and expression of T cell-mediated immunity. IX. Activation of alloimmune memory lymphocytes into specific secondary CTL by syngeneic NAGO-oxidized stimulator cells. (1974) (5)
YY1 Silencing Induces 5-Fluorouracil-Resistance and BCL2L15 Downregulation in Colorectal Cancer Cells: Diagnostic and Prognostic Relevance (2021) (5)
Molecular mechanism of natural killer cell-mediated cytotoxicity. (1987) (5)
Nitric Oxide Donors Sensitize Resistant Cancer Cells to Apoptosis Induced by Chemotherapy: Molecular Mechanisms of Sensitization (2017) (5)
Regulation of B-cell lymphoma growth in syngeneic SJL/J mice. establishment of tumor dormancy following administration of anti-CD4 monoclonal antibody into tumor-bearing mice. (1993) (5)
CD8+ lymphocytes participate in the development of chronic rejection. (2001) (5)
Murine spleen lymphocytes bearing receptors for peanut agglutinin. VII Separation and functional characterization. (1981) (5)
Opsonization of antitumor reactive lymphocyte in SJL/J mice bearing spontaneous or transplanted reticulum cell sarcomas (RCS). (1979) (5)
Special collection: Nitric oxide in cancer☆ (2015) (5)
Development of rituximab-resistant B-NHL clones: an in vitro model for studying tumor resistance to monoclonal antibody-mediated immunotherapy. (2011) (5)
Hierarchy of in vitro sensitivity and resistance of tumor cells to cytotoxic effector cells, cytokines, drugs and toxins (2005) (5)
Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers. (1990) (5)
Resistance of Cancer Cells to CTL-Mediated Immunotherapy (2015) (5)
Antibody-forming cells with specificity for syngeneic and allogeneic (thymocyte) tissue antigens following lipopolysaccharide mitogenic stimulation. (1977) (5)
Rituximab-Mediated Inhibition of the Transcription Repressor Yin-Yang 1 (YY1) in NHL B Cell Lines: Upregulation of Fas Expression and Sensitization to Fas-Induced Apoptosis. (2004) (4)
Transdifferentiation of Monocytes into Endothelial Cells by Pleiotrophin. (2005) (4)
Autoreactive and alloreactive antibody-forming cells (AFC) following lipopolysaccharide (LPS) activation of normal and memory lymphocytes. (1980) (4)
Pentoxifylline suppresses interleukin-2-mediated activation of immature human natural killer cells by inhibiting endogenous tumor necrosis factor-alpha secretion (2005) (4)
Prognostic Significance of Both the Cytoplasmic and Nuclear Overexpression of Yin-Yang 1 (YY1) among Patients with Multiple Myeloma (MM) (2008) (4)
[quantitative determination of proteins in human tears]. (1967) (4)
Characteristics of rituximab-resistant B-NHL clones: deficiencies in rituximab-mediated changes in lipid raft microdomains and cell signaling (2006) (4)
Anti-VEGF Antibody Treatment Markedly Inhibits Tumor Growth in SCID-hu Models of Human Multiple Myeloma. (2006) (4)
Novel Therapeutic Applications of Nitric Oxide in the Inhibition of Tumor Malignancy and Reversal of Resistance (2010) (4)
Resistance to Immunotherapeutic Antibodies in Cancer (2013) (4)
Liposomes can function as targets for natural killer cytotoxic factor but not for tumor necrosis factor. (1989) (4)
Resveratrol as a Sensitizer to Apoptosis-Inducing Stimuli (2005) (4)
Mechanism of Natural Killer Cell‐Mediated Cytotoxicity a (1988) (4)
ROLE OF NATURAL KILLER CYTOTOXIC FACTORS (NKCF) IN THE MECHANISM OF NK CELL MEDIATED CYTOTOXICITY (1982) (4)
Computational Analyses of YY1 and Its Target RKIP Reveal Their Diagnostic and Prognostic Roles in Lung Cancer (2022) (4)
SELECTIVE LYSIS OF NATURAL KILLER (NK) SENSITIVE TARGETS BY SOLUBLE CYTOTOXIC FACTORS (NKCF) (1982) (4)
Therapeutic Applications of Nitric Oxide in Cancer and Inflammatory-related Disorders (2018) (4)
Role of the Transcription Factor Yin Yang 1 and Its Selectively Identified Target Survivin in High-Grade B-Cells Non-Hodgkin Lymphomas: Potential Diagnostic and Therapeutic Targets (2020) (4)
Use of immunologically modified bacteriophage T4 in detection of antibodies to nucleic acids. (1972) (4)
Soluble cytotoxic factors and the mechanism of NK cell mediated cytotoxicity. (1982) (4)
Involvement of Yin Yang 1 (YY1) Expression in T-Cell Subsets Differentiation and Their Functions: Implications in T Cell-Mediated Diseases. (2019) (4)
The Breast Cancer Protooncogenes HER2, BRCA1 and BRCA2 and Their Regulation by the iNOS/NOS2 Axis (2022) (4)
The Forgotten YY2 in Reported YY1 Expression Levels in Human Cancers. (2017) (4)
Up-RegulationYin Yang 1 Inhibition and Death Receptor 5 Suppressor Raf Kinase Inhibitor Protein via TRAIL-Induced Apoptosis by the Metastatic Regulation of Tumor Cell Sensitivity to (2007) (4)
Rituximab Sensitizes TRAIL-Resistant B-NHL Lines to Apoptosis by Both TRAIL and Fully Humanized Antibodies Targeting TRAIL-R1 (Mapatumumab) and TRAIL-R2 (Lexatumumab). (2007) (4)
Non-H-2-linked control of in vivo growth of SJL/J-derived reticulum cell sarcoma in recombinant inbred strains between BALB/cKe and SJL/J mice. (1985) (4)
Regulation of the TRAIL receptor DR5 expression by the transcription repressor Yin Yang 1 (YY1) (2005) (3)
DETANONOate is a potent chemo\radio-sensitizing agent in colon and colorectal cancers as assessed in in vitro and in vivo established tumor xenografts (2010) (3)
Modulation of T-dependent cell-mediated immune responses by antigen-reactive cell opsonization and active suppression. (1978) (3)
Intimate host-tumor interaction in the spontaneous reticuium cell sarcoma of SJL/J mice: Is it an exceptional case? (1985) (3)
Proceedings of the First International Symposium on Physical, Chemical, and Biological Properties of Stable Water (I[E][TM]) Clusters : Los Angeles, California, 6 December 1997 (1998) (3)
Natural Killer Cells in HIV Infection (1996) (3)
Computational Evaluation of Yin Yang 1 Transcript Levels in the Spectrum of B-cell Neoplasia (2010) (3)
Sensitization of AIDS related non-Hodgkin's B lymphoma cell lines to cytotoxic drugs toxins by interferon-gamma. (1996) (3)
Inhibition of NF-Kb Cell Signaling and Induction of the Metastasis Suppressor and Immune Surveillance Cancer Gene RKIP Expression in B-NHL by the Novel Humanized BM-Ca Anti-CD20 Monoclonal Antibody: Implication in Chemo and Immune-Sensitization (2008) (3)
The Novel Proteasome Inhibitor NPI-0052 Induces the Expression of Raf-1 Kinase Inhibitor Protein RKIP) in B-NHL via Inhibition of the Transcription Repressor Snail: Roles of Snail and RKIP in Sensitization to TRAIL Apoptosis (2008) (3)
Cytotoxic effect of diphtheria toxin used alone or in combination with other agents on human renal cell carcinoma cell lines (2004) (3)
The Role of RKIP in the Regulation of EMT in the Tumor Microenvironment (2022) (3)
Membrane‐mediated cytotoxicity (1987) (3)
RKIP: A Pivotal Gene Product in the Pathogenesis of Cancer (2021) (3)
Augmentation of cytotoxicity of lymphokine activated killer cells on ovarian tumor cells by various biological response modifiers. (1990) (3)
LECTIN-DEPENDENT NATURAL KILLER CELLULAR CYTOTOXICITY IN MICE (NK-LDCC): A NEW SUBPOPULATION OF NK-LIKE CYTOTOXIC CELLS (1982) (3)
The Humanized Anti-CD40 Antibody SGN-40 Inhibits Tumor Growth in LAGκ-1A, a CD40+ Mouse Model of Human Multiple Myeloma. (2006) (3)
Tears as carriers of antibodies. 1. Presence of antibodies to diverse antigens in rabbit tears. (1967) (3)
ZIO-101, a Novel Organic Arsenic, Inhibits Human Myeloma Cell Growth in a SCID-hu Model. (2006) (3)
Studies on the induction and expression of T-cell-mediated immunity. XIII. Membrane-associated antigens of cytotoxic T lymphocytes involved in cytotoxicity. (1983) (3)
Role of plasma membrane fluidity alterations in tumor cell sensitization to apoptosis-inducing stimuli: Therapeutic implications (2006) (3)
Opsonization of anti-tumor reactive lymphocytes in sjl/j mice bearing spontaneous reticulum cell sarcomas (rcs). Abstr. (1978) (2)
High Expression of Transcription Factor Yin Yang 1 and Multidrug Resistance Protein in Early B-Cell Precursors in Childhood Acute Lymphoblastic Leukemia. (2009) (2)
Immunoregulation and Cytotoxicity by Tumor Necrosis Factor1 (1988) (2)
Inverse Relationship Between the Transcription Repressor Yin Yang 1 (YY1) and the TRAIL Death Receptor DR5 in AIDS-Related Non-Hodgkin's Lymphoma Tissues: Potential Prognostic Biomarkers and Targets for Therapeutic Intervention. (2009) (2)
RKIP Pleiotropic Activities in Cancer and Inflammatory Diseases: Role in Immunity (2021) (2)
Blocking of the induction and expression of immunologically functional T lymphocytes by rat antiactivated T-cell serum. (1982) (2)
Regulation of NKG2D by RKIP: Implications on NK-mediated cytotoxicity and cytokine production (2021) (2)
Reversal of Drug Resistance: Synergistic Anti-Tumor Cytotoxic Activity by Combination Treatment with Drug and TNF or Toxins (1993) (2)
The potent histone deacetylase inhibitor vorinostat, in combination with melphalan, markedly enhances the anti-myeloma effects of chemotherapy in vitro and in vivo (2008) (2)
Resistance to Immunotoxins in Cancer Therapy (2015) (2)
Expression of alien histocompatibility antigens on SJL/J tumors detected by cell-mediated and serological analyses (1981) (2)
Expression, Role in Transformation and Prognostic Significance of the Transcription Factor Yin Yang 1 (YY1) in Non-Hodgkin’s Lymphoma: Analyses in NHL Tissues by Experimental and Bioinformatic Approaches (2008) (2)
Direct and Enhanced Cytotoxicity of the Bcl-2 Family Inhibitor GX15-070 on Rituximab-Sensitive and Rituximab-Resistant B-NHL Clones. (2007) (2)
Abstract 5450: High expression of Krüppel-Like Factor 4 (KLF4) and its regulation by Yin Yang 1 (YY1) in non-Hodgkin's B-cell lymphomas: clinical implication. (2013) (2)
Preferential induction of TNF-alpha and IL-1beta and inhibition of IL-10 secretion by human peripheral blood monocytes by synthetic aza-alkyl lysophospholipids. (1999) (2)
Detection of a transforming gene in spontaneous reticulum cell sarcoma of SJL/J mice: genetically linked and host-dependent neoplasia. (1987) (2)
Surface expression of alien hybrid IE/C antigens on the reticulum cell sarcoma of SJL/J mice. (1981) (2)
Sensitization of Immune-Resistant Tumor Cells to CTL-Mediated Apoptosis via Interference at the Dysregulated NF-κB/Snail/YY1/PI3K/RKIP/PTEN Resistant Loop (2015) (2)
The rituximab-PKCζ/Raf-1/mTOR connection (2008) (2)
Effects of a Novel Histone Deacetylase Inhibitor, PXD101, When Used as Monotherapy or in Combination with Bortezomib on Tumor Growth in Mouse Models of Human Multiple Myeloma. (2006) (2)
Antibacterial activity of adriamycin against bacillus Calmette-Guerin. (1997) (2)
Abstract A53: Yin Yang 1 (YY1) regulates EMT via transcriptional activation of Snail and its overexpression in cancer stem cells (CSCs) in prostate cancer: Clinical significance. (2013) (2)
New Targets identified for therapeutic intervention in the reversal of rituximab and drug resistant AIDS-B-NHL. (2006) (2)
Rituximab-Mediated Molecular Cell Signaling Via CD20 in B-NHL Cell Lines: Autonomy from Cross-Linking with Tumor FcRs. (2004) (2)
Regulation of reticulum cell sarcoma tumor growth in SJL/J mice by a serum inhibitor affecting T-cell proliferation. (1985) (2)
Sensitization of B-NHL resistant tumor cells overexpressing Bcl-xL to TRAIL-induced apoptosis by the novel proteasome inhibitor Salinosporamide A (NPI-0052) (2007) (2)
Overexpression of the Transcription Factor Yin Yang 1 in Non-Hodgkin Lymphoma is associated with Chemo-Immune Resistance (2016) (2)
Analysis of YY1 and XIAP Expression, Proteins That Regulate Resistance, in AIDS-NHL Tissue Arrays. (2005) (1)
TRAF6 Dominant Negative Peptides Block Intracellular Signaling Resulting in Anti-Myeloma and Anti-Bone Resorptive Effects in Multiple Myeloma (2011) (1)
Immune response to spontaneous reticulum cell sarcoma (rcs) in sjl/j mice. Abstr. (1975) (1)
Smog eye irritation: effect of air pollution on the tear protein pattern. (1969) (1)
Nitric Oxide (NO) induced sensitization of tumor cells to TRAIL-mediated apoptosis via induction of RKIP and DR5 expression and inhibition of YY1 (2007) (1)
Mechanism of T-dependent cytotoxicity: role of papain-sensitive non class I MHC target molecules and expression of target antigen for cytotoxicity. (1985) (1)
Proposal for Classification of Leukocyte‐Associated Cytolytic Molecules: Denver, Colorado, September 28, 1986 (1987) (1)
Abstract 2290: A novel function in metastasis for YY1 overexpression in the initiation of the EMT phenotype (2010) (1)
Involvement of TNF-α mRNA downregulation in tumor cell sensitivity to TNF-α Pentoxifylline enhances sensitivity of a human ovarian cancer cell line (OVC-8) to TNF-α (1993) (1)
Blocking Pleiotrophin Activity Inhibits Multiple Myeloma (MM) Cell Growth In Vitro and in a Severe Combined Immunodeficient (SCID)-hu Murine Model of Human MM. (2005) (1)
B1. Nitric oxide induces RKIP expression and sensitizes tumor cells to TRAIL-mediated apoptosis via inhibition of both NF-κB and YY1 and upregulation of DR5 (2007) (1)
[TNF and TNF receptors: structure, mechanism of action, role in disease and therapy]. (1993) (1)
Chemosensitization of Drug and Rituximab-Resistant Daudi B-NHL Clones to Drug-Induced Apoptosis by the Proteasome Inhibitor NPI-0052. (2005) (1)
Cytotoxic Activity of Anti-CD20-hIFN-α on Rituximab-Resistant B-NHL Clones and Synergy with Chemotherapy, (2011) (1)
Sensitivity of drug-resistant B-cell lines from AIDS-related non-hodgkins-lymphoma to newly synthesized podophyllotoxin derivatives and aza-alkyllysophospholipids - enhanced sensitization by pretreatment with interferon-gamma. (1994) (1)
Abstract 2162: Inhibition of the metastasis suppressor RKIP by EZH2 and YY1 (2011) (1)
Nitric Oxide Inhibits Tumor Cell Metastasis via Dysregulation of the NF-κB/Snail/RKIP Loop (2010) (1)
Inappropriate alloantigen-like specificities detected on reticulum cell sarcoma of sjl/j mice. Abstr. (1979) (1)
Comprar Sensitization of Cancer Cells for Chemo/immuno/Radio-therapy | Bonavida, Benjamin | 9781934115299 | Springer (2008) (1)
Molecular Mechanism by Which Rituximab Sensitizes B-NHL Cells to TRAIL Apoptosis: Induction of RKIP and DR5 Expression Via Inhibition of NF-Kb, Snail, and YY1. (2008) (1)
Historical Perspectives of the Role of NO/NO Donors in Anti-tumor Activities: Acknowledging Dr. Keefer's Pioneering Research (2021) (1)
Smac/DIABLO: A Proapoptotic Molecular Target in Renal Cell Cancer (2009) (1)
Reversal of Rituximab-Resistant AIDS-B-NHL Clone to Chemotherapeutic Drug-Induced Apoptosis by Bortezomib and DHMEQ. (2005) (1)
A Novel Method for Screening Anti-Angiogenic Compounds: The Chorionicallantoic Membrane (CAM)/Feather Bud (FB) Assay. (2008) (1)
Gonorrhea: Immune Escape and Immunotherapeutic Strategies (2016) (1)
Abstract 3617: Inhibition of KLF4 expression in resistant B-NHL cell lines inhibited cell growth and sensitized the cells to drug-induced apoptosis (2015) (1)
Molecular interactions in T-cell mediated cytotoxicity: discrimination between the binding and lethal hit stages of cytolysis. (1982) (1)
Sensitization of Rituximab-Sensitive and Rituximab-Resistant B-NHL Cell Lines/Clones to TRAIL-Induced Apoptosis by Bortezomib and NF-κB Inhibitors. (2005) (1)
A spontaneous sarcoma dependent on host tumor‐specific immune lymphocytes (1989) (1)
Targeting the Over-Expressed Transcription Factor Yin-Yang 1 (YY1) Sensitizes Resistant Multiple Myeloma (MM) Cell Lines to Apoptosis by Bortezomib or Melphalan, (2011) (1)
Co-Overexpression of YY1 and Gp-170 (MDR1) in Childhood Acute Lymphocytic Leukemia (ALL): Transcription Regulation of Gp-170 by YY1 and Prognostic Significance, (2011) (1)
Cytotoxic properties of a new synthetic demethylpodophyllotoxin derivative, BN 58705, against human tumor cell lines (2004) (1)
Nitric Oxide (NO): A Multifaceted Target for Reversal of Cancer Cell Pleiotropic Properties by NO-Modulating Therapies (2019) (1)
2-Methoxyestradiol Sensitizes B-NHL Cells to TRAIL-Mediated Apoptosis Via Inhibition of HIF-1α, NF-κ B, YY1 and Induction of DR5 Expression. (2006) (1)
Pleiotropic activities of RKIP in cancer: Role in survival, EMT, chemo-immuno-resistance, and autophagy (2020) (1)
Blockage of TRAF6 by Dominant Negative Peptides to Inhibit Multiple Myeloma (MM) Cell Proliferation and Osteoclast Formation through NF-κB, JNK and AKT Signal Transduction Pathways (2010) (1)
Aims and Scope for Volume 1 “Nitric Oxide (Donor/Induced) in Chemosensitization” (2017) (1)
Expression of superantigen-like specificities on murine sjl/j-B lymphomas - antitumor v-Beta-17a+ T-lymphocytes use a diverse set of T-cell receptor v-alpha-chain gene-sequences. (1994) (1)
Dual Roles of Raf-1 Kinase Inhibitor Protein in the Regulation of Both Tumor Cell Resistance to Apoptotic Stimuli and Epithelial to Mesenchymal Transition (2011) (1)
Inhibition of Snail-induced Epithelial-Mesenchymal Transition and Induction of the Tumor Metastasis Suppressor Gene Raf-1 Kinase Inhibitor Protein (RKIP) by DETANONOate (2010) (1)
Lack of Binding of Monoclonal Protein Produced by Multiple Myeloma (MM) Cells to FcγRIIb Reduces Immunoreceptor Tyrosine-Based Inhibitory Motif (ITIM) Signaling and Provides the Rationale for a Novel Therapeutic Approach to MM (2010) (1)
Preface: Probiotics and Immunity (2016) (1)
FUNCTIONAL AND BIOCHEMICAL CHARACTERIZATION OF NATURAL KILLER CYTOTOXIC FACTORS AND THEIR ROLE IN THE NK LYTIC MECHANISM1 (1985) (1)
YY1 expression and PD-1 regulation in CD8 T lymphocytes (2021) (1)
Predictors of natural killer cell-mediated cytotoxicity deficiency in advanced heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. (1997) (1)
Rituximab sensitizes resistant B-NHL cell lines to the proteasome inhibitor NPI-0052-induced apoptosis. (2006) (1)
Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic intervention (2014) (1)
Identification of Novel Receptors on Myeloma Cells and Monocytes That Contribute to Myeloma Tumor Proliferation and Angiogenesis. (2005) (1)
Regulation of the c-myc Oncogene by the Circadian Clock and Oncogenesis. (2021) (1)
Overexpression of inhibitor of apoptosis protein XIAP in human prostate cancer (2005) (1)
Rituximab-Mediated Inhibition of the p38 MAPK and NF-κB Survival Pathways In Vitro and Validation in Nude Mice Bearing the Raji B-NHL Tumor. (2006) (1)
Stable Water Clusters−Mediated Molecular Alterations in Human Melanoma Cell Lines (2012) (1)
Increased M2 Macrophages and Higher Levels Of The Tribble Family Member Trib1 In Monocytes Are Associated With Progressive Disease In Multiple Myeloma (MM) Patients (2013) (1)
In Honor of Professor Demetrios A. Spandidos (2017) (1)
Pterostilbene: A Novel Histone Deacetylase 1 Inhibitor (HDACi1) Demonstrating Efficacy in Multiple Myeloma. (2009) (1)
Chemo-Immunosensitization of Resistant B-NHL as a Result of Rituximab (anti-CD20 mAb)-Mediated Inhibition of Cell Survival Signaling Pathways (2008) (1)
Experimental Therapeutics , Molecular Targets , and Chemical Biology Pivotal Roles of Snail Inhibition and RKIP Induction by the Proteasome Inhibitor NPI-0052 in Tumor Cell (2009) (1)
Decreased LIMD1 Gene Expression Is Associated with HIF-1α Over-Expression and Angiogenesis in Multiple Myeloma (2012) (1)
Circulating Bcma Binding to Its Ligand BAFF Prevents Normal Antibody Production in Multiple Myeloma Patients (2014) (1)
This information is current as TRAIL-Enhanced Apoptosis in Cancer Cells Inhibitor NPI-0052 Contributes to its Expression by the Novel Proteasome Repressor Activity of DR5 Transcription and Inhibition of Yin Yang 1-Dependent (2013) (1)
A Bioinformatics Approach Revealed a Differential Expression of RKIP-Related Genes in Pre-Multiple Myeloma and Multiple Myeloma: Clinical Implications (2015) (1)
Clinical Significance of RKIP and Phosphorylated RKIP Expression in Human Cancers (2011) (1)
Unique Pattern of Raf-1 Kinase Inhibitory Protein (RKIP) Expression in Multiple Myeloma (MM): RKIP Overexpression and RKIP Phosphorylation Is Common in MM Tumor Cells (2008) (1)
KLF4 and YY1 Are Resistant Factors in NHL and Potential Therapeutic Targets: The New Resistant NF-κb/YY1/KLF4/Bcl xL /Mcl-1 Axis (2015) (1)
Nitric Oxide—Induced Immunosensitization to Apoptosis by Fas-L and TRAIL (2008) (1)
Abstract 4687: Oncogenic role of the transcription factor YY1 and its target Survivin in non-Hodgkin's lymphoma (2020) (0)
Preface: First International Conference on Nitrosylation in Oncology and Immunology; Speakers' Presentations (2012) (0)
Anti-Myeloma Effects of the Janus Kinase 2 (JAK2) Inhibitor SAR503 Alone and in Combination Treatment (2012) (0)
The role of soluble alloantigens in the induction of efferent and afferent blocking of cell mediated immunity. Abstr. (1973) (0)
Sensitization of prostate cancer cells to TRAIL-induced apoptosis by CDDP: Involvement of NF-κB, YY1 and RKIP in upregulation of DR5 expression (2005) (0)
Rituximab-Mediated Inhibition of the PI3K-Akt Survival Signaling Pathway in B-NHL Cell Lines Leading to Downregulation of Bclxl Expression and Chemosensitization. (2005) (0)
Chemosensitization of Drug-Resistant Ramos B-NHL to Drug-Induced Apoptosis: YY1 Expression Is Decreased in Response to Cytoskeletal-Interacting Drugs. (2005) (0)
Cytotoxicity of Genetically Engineered Fusion Protein with CD154 Peptide Mimetic (OmpC-CD154 p ) on B-NHL Cell Lines. (2007) (0)
Preface: Circadian Rhythm and Oncogenesis Part 2 (2021) (0)
Overexpression of RKIP and its cross-talk with several regulatory gene products in multiple myeloma (2017) (0)
Velcade ) with the Proteasome Inhibitor Bortezomib Dendritic Cell-Activated Immune Responses Immunosensitization of Tumor Cells to (2006) (0)
Further Improvement of Clinical Application of TNF and Antitumor Therapeutics (1990) (0)
Characterization of Cancer Stem Cells in Multiple Myeloma (2008) (0)
Synergistic Effects, Cytokine Cascades and Interactions (1990) (0)
Mechanism of apoptosis induced by an IgG3-avidin fusion protein specific for the human transferrin receptor (2005) (0)
Over Expression of YY1 and RKIP in Multiple Myeloma (Cell Lines and MM Tissues). (2006) (0)
Opsonization of tumor-reactive T cells in SJL/J mice bearing syngeneic tumors (2004) (0)
RCS tumor-host interactions: tumor growth dependence on L3T4+ T cells and its regulation by suppressor cells. (1987) (0)
Membrane-mediated cytotoxicity : proceedings of a Cetus-UCLA Symposium held in Park City, Utah, March 9-16, 1986 (1987) (0)
TRAF6-Dominant Negative Peptides Show Potent Inhibitory Effects On Multiple Myeloma, Osteoclast Formation and Bone Resorption. (2009) (0)
TNF in Autoimmunity (1990) (0)
PREFACE: Contrasting Roles of KLF4 as an Oncogene or Tumor Suppressor (2016) (0)
13 – Immune Response to Lysozyme: Limited Heterogeneity Caused by Restricted T Cells (1974) (0)
Blockage of TRAF6 Signaling Inhibits Osteoclast Formation and Tumor Cell through Blocking the NF-kB and JNK Pathways in Multiple Myeloma. (2007) (0)
Vivid Memories of Sercarz's Traineeship and Am Indebted to Him for My Professional Career. (2020) (0)
Unique Pattern of Raf-1 Kinase Inhibitory Protein (RKIP) Expression in Multiple Myeloma (MM) Compared to Other Tumor Types: Overexpression of RKIP and a Phosphorylated RKIP Is Common in MM Tumor Cells. (2007) (0)
Involvement of natural killer cells in the pathogenesis of lymphomas: Therapeutic implications (2021) (0)
Tumor Resistance to Antibody-Mediated Immunotherapy and Reversal of Resistance: Rituximab as Prototype (2013) (0)
SPECIFIC TARGET CELL LYSIS BY SUPERNATANTS DERIVED FROM ALLOIMMUNE MURINE CYTOTOXIC T LYMPHOCYTES: POSSIBLE ROLE OF A LYMPHOTOXIN-T CELL RECEPTOR COMPLEX (1979) (0)
A19. Chemo and immuno-sensitizing activities of nitric oxide (NO) and reversal of tumor resistance to apoptotic stimuli: Therapeutic implications (2007) (0)
Clinical Significance of the Inhibition of YY1 Activity and Expression by Therapeutic Anti-Cancer Antibodies (2010) (0)
Yin Yang 1 (YY1) Acting Primarily As an Oncogene and Rarely As a Tumor Suppressor in Distinct Hematological Malignancies: Prognostic and Therapeutic Implications (2016) (0)
Cytotoxic activity against resistant human tumor-cell lines by 2 synthetic demethylpodophyllotoxin derivatives - a single stereoisomeric change prevents cell-death by apoptosis. (1993) (0)
Reversal of Drug/TRAIL-Resistant B-NHL Cells to Apoptosis by the Combination of Rituximab (anti-CD20) and Either Mapatumumab or Lexatumumab (2010) (0)
Overexpression of Raf Kinase Inhibitor Protein (RKIP) in Multiple Myeloma and Its Molecular Signature (2016) (0)
Title Page / Contents / Acknowledgements / Preface (1992) (0)
Circulating Tie2-Expressing Cells Are Increased in Multiple Myeloma Patients, Correlate with Serum Pleiotrophin Levels and May Develop from This Myeloma Angiogenic and Growth Factor. (2005) (0)
Abstract 3374: BRAF and NRAS mutations in melanoma regulate the phosphorylation and inactivation of RKIP, the metastasis suppressor and immune surveillance cancer gene product (2010) (0)
Reversal of Resistance to Anti-CD20 Antibody Therapies: Targeting Intracellular Resistant Factors. (2020) (0)
Abstract 806: Upregulation of Krüppel-like Factor 4 (KLF-4) expression as a potential tumor progression gene product in non-Hodgkin's lymphoma (2010) (0)
MIG/CXCL9 neutralization attenuates chronic rejection of transplanted hearts (2003) (0)
Inhibition of B-NHL Tumor Xenografts Following Treatment with Galiximab (Anti-CD80 mAb) and Potentiation When Combined with Chemotherapy (2012) (0)
RKIP: A Pivotal Gene Product in the Pathogenesis of Cancer (2022) (0)
Molecular interactions in t cell-mediated cytotoxicity: antigen nonspecific cytotoxicity following oxidative modification of membrane carbohydrates of ctl. Abstr. (1981) (0)
Abstract 3499: Identification of a novel mechanism by which the BH3 mimetic obatoclax sensitizes non-Hodgkin's lymphoma tumor cells to TRAIL-mediated apoptosis (2011) (0)
In Memoriam: My Unforgettable Journey with Eli E. Sercarz (2020) (0)
COMMENTARY: Clinical Applications of Photodynamic Therapy (2011) (0)
Serological analysis of ie-like ia molecules on spontaneous reticulum cell sarcoma of sjl/j mice. Abstr. (1982) (0)
Induction of Raf-1 Kinase Inhibitory Protein (RKIP) by the Proteasome Inhibitor NPI-0052 and Reversal of B-NHL Resistance to Apoptosis. (2007) (0)
Effects of TNF on Mammalian Cells: Differentiation, Proliferation and Cytotoxicity (1990) (0)
Preface: special issue on yin yang 1 and oncogenesis. (2011) (0)
In Memorium The Unforgettable Journey and Legacy (2020) (0)
Preface: Autophagy and Oncogenesis (2018) (0)
Commentary: Photodynamic Therapy-Induced Oxidative Stress and the Circadian Rhythm. (2021) (0)
The trimeric engineered fusion protein with CD40L peptide mimetic (OmpC-CD154p), induced apoptotic signaling on B-NHL cell lines: Higher effect than the recombinant CD40L or anti-CD40 mAb. (2008) (0)
Tumor and Stem Cell Biology Polycomb Protein EZH 2 Regulates Tumor Invasion via the Transcriptional Repression of the Metastasis Suppressor RKIP in Breast and Prostate Cancer (2012) (0)
Effect of PAF and inhibitors in the natural killer cell-mediated cytotoxic reaction (1987) (0)
Targeting the V-Type Immunoglobulin Domain-Containing Suppressor to T Cell Activation (VISTA) with Agonist Monoclonal Antibodies in Autoimmunity. (2022) (0)
Chemosensitization of resistant ovarian tumor cells to anti-Fas mediated cytotoxicity and apoptosis. (1996) (0)
B202 A Novel Angiogenesis Model for Screening Antiangiogenic Compounds (2009) (0)
Human and Rodent Natural Killer Cytotoxic Factors (NKCF) (1988) (0)
Post-binding inhibition of ADCC by monoclonal anti-HLA antibodies directed against the effector K cell (1982) (0)
Actinomycin D to Apo-2 Ligand-Induced Apoptosis by Sensitization of AIDS-Kaposi ' s Sarcoma Cells (1999) (0)
Histamine Receptor-Bearing Leukocytes (HRL) (1974) (0)
Synergy in Apoptosis Is Achieved in B-NHL by the Combination of Rituximab and the Novel Proteasome Inhibitor NPI-0052: Pivotal Role of Induction of the Immune Surveillance Cancer Gene Product RKIP (2008) (0)
A Novel Targeted Therapeutic Approach to Multiple Myeloma Using Tumor Specific Anti-Sense RNA Sequences (2008) (0)
Induction and Secretion of TNF-α during the Maturation and Differentiation of Human Natural Killer Cells1 (1992) (0)
Serum Pleiotrophin Is a New Multiple Myeloma Tumor Marker That Also Predicts Clinical Status. (2005) (0)
In Vivo Anti-Tumor Efficacy of Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®) in Multiple Myeloma (2008) (0)
IS THERE A RELATIONSHIP BETWEEN EFFECTOR-TARGET CELL BINDING AND CELL-MEDIATED CYTOTOXICITY? (1977) (0)
Title Page / Contents / Acknowledgments / Preface (1990) (0)
Abstract 1928: Resistance of human melanoma to MART-1/HLA A2.1 specific CTL (F5 CTL)-killing: poor recognition, low MART-1 expression and reversal of resistance (2010) (0)
In Memory of Lee Goodglick: A Friend and A Scholar (2015) (0)
CHAPTER 16 – Principles of Tumor Immunology (2006) (0)
Role in Lymphocyte and Macrophage-Mediated Cell Lysis: Other Cytotoxic Lymphokines and Monokine (1990) (0)
Identification of Differentially Expressed Genes in the Rituximab- Resistant Clone (Ramos RR1) Compared to Wildtype Sensitive Ramos: Therapeutic Implications in Rituximab-Resistance (2008) (0)
FIRST INTERNATIONAL WORKSHOP ON "PROGNOSTIC AND THERAPEUTIC APPLICATIONS OF RKIP IN CANCER" (2011) (0)
Chemokine MIG/CXCl9 stimulates CD4 T lymphocyte proliferation and IFN-γ expression (2004) (0)
Lactobacillus casei Utilization in inmunoestables compositions. (2001) (0)
Regulation of the Cancer Stem Cell Phenotype by Raf Kinase Inhibitor Protein via Its Association with Kruppel-Like Factor 4 (2016) (0)
Nomenclature Standardization and Measurement of Lymphokines in vivo (1990) (0)
Bacillus Calmette-Guerin (BCG) in the treatment of superficial bladder cancer. (1997) (0)
Autoantibodies Directed Against Moesin C 471-577 /N 1-297 Are Novel and Specific Biomarkers of Immune Thrombocytopenic Purpura (ITP), (2011) (0)
Resistance to anti-cancer antibody-mediated immunotherapy (2020) (0)
Aims and Scope for Series “Cancer Sensitizing Agents for Chemotherapy” (2021) (0)
Cross Talk between the Circadian Clock Proteins and TP53 in Cancer and Therapeutic Significance. (2021) (0)
YAC-1 variant clones selected for r cytotoxic factors are also resistant I cell-mediated cytotoxicity (2016) (0)
Contents, Vol. 33, 1968 (1968) (0)
In silico Tissue-Based Expression Analysis of YY1 and Cancer Stem Cell (CSC) Transcription Factors in Hematological Malignancies: Unraveling New Therapeutic Targets (2015) (0)
Overexpression of YY1 Regulates the Resistance of Cancer Stem Cells: Targeting YY1 (2019) (0)
Activation of allosensitized memory lymphocytes into secondary cytotoxic T lymphocytes by third-party stimulator cells: genetic mapping of the stimulating antigens. (1981) (0)
Largazole, a Novel Cyclic Peptide Histone Deacetylase Inhibitor, Demonstrates Anti-MM Effects Alone and Increases the Anti-MM Effects of Bortezomib. (2009) (0)
Abstract 664: Galiximab (anti-CD80 mAb) sensitizes TRAIL-resistant B-lymphoma to TRAIL-induced apoptosis via inhibition of the transcription repressor Yin Yang 1 (YY1) (2010) (0)
CANCER RESISTANCE IS MEDIATED BY THE UPREGULATION OF SEVERAL ANTI-APOPTOTIC GENE PRODUCTS VIA THE INOS/NO PATHWAY: THERAPEUTIC IMPLICATIONS (2023) (0)
Pleiotrophin Promotes Myeloma Proliferation through the Activation of Known and Novel Receptors. (2006) (0)
Cytotoxicity of new aza-alkyl lysophospholipids against drug-sensitive and resistant human ovarian tumor-cell lines - role of free-radicals and potentiation of cytotoxicity by tnf-alpha and cddp. (1994) (0)
Normal human oral keratinocytes are more sensitive to N-methyl-N'-nitro-N-nitrosoguanidine-induced cytotoxicity and apoptosis than HPV-immortalized oral keratinocytes. (1997) (0)
Expression of alien ia tumor antigens resulting from gene complementation between the ia and ie subregions. Abstr. (1981) (0)
Nitric Oxide Sensitizes B-NHL Cells to TRAIL-Mediated Apoptosis through Induction of RKIP, Inhibition of YY1 and Upregulation of DR5. (2006) (0)
Part 2 Preface: Immune Checkpoint Inhibitors and Adverse Autoimmune Manifestations. (2022) (0)
Overcoming drug resistance of ovarian carcinoma cell lines by treatment with combination of TNF- α /anti-Fas antibody and chemotherapeutic drugs or toxins (1995) (0)
Frequent Dysregulation of Fc Gamma Receptor IIb (Fc γRIIb) and Immunoreceptor Tyrosine-Based Inhibitory Motif (ITIM) Signaling Occurs in Multiple Myeloma (MM) Patients (2011) (0)
Preface: Eli Sercarz Memorial Issue, Part II (2020) (0)
Inhibition of the RKIP and PTEN-Transcription Repressor Snail in B-NHL by the Proteasome Inhibitor NPI-0052: Roles of RKIP and PTEN Induction in the Reversal of Resistance to TRAIL Apoptosis. (2009) (0)
Expression of the p38 MAPK/NF-kB signaling pathway and over-expression of Bcl-2/Bcl-XL predict poor response in Diffuse Large B-cell Lymphoma: Potential biomarkers and targets for therapeutics. (2008) (0)
Pentoxifylline enhances sensitivity of a human ovarian cancer cell line (OVC-8) to TNF-alpha. (1993) (0)
Selective inhibitory effects of 4-hydroperoxycyclophosphamide (4-HCY) on T and B functions in man (1982) (0)
Pivotal Role of Nitric Oxide in Chemo and Immuno Sensitization of Resistant Tumor Cells to Apoptosis (2015) (0)
Upregulation of Krüppel-Like Factor 4 (KLF-4) Expression as a Potential Tumor Progression Gene Product in Non-Hodgkin's Lymphoma. (2009) (0)
Acknowledgement of reviewers 2012 (2013) (0)
Multiple Myeloma (MM) Highly Expresses CGEN-928 and the Anti-CGEN-928 TM21 Antibody Markedly Inhibits the Growth of MM Cells and Enhances the Anti-Myeloma Effects of Dexamethasone, Melphalan and Bortezomib (2010) (0)
Seminar report and Meeting abstract VIIIth Meeting of the European Association for Cancer ResearchReticulum cell sarcoma of SJL/J mice as an experimental model system for molecular analysis of genetically linked spontaneous neoplasias (1985) (0)
C35. Nitric oxide mimics rituximab (chimeric anti-CD20 mAb)-induced chemo/immuno-sensitization of resistant B-non Hodgkin’s lymphoma (2007) (0)
HYBRID Ia MOLECULES ON RETICULUM CELL SARCOMAS (2003) (0)
Evaluation of serum B-cell maturation antigen in multiple myeloma. (2012) (0)
Membrane interactions involved in the cytolysis of target cells. Nonspecific lysis of nago modified target cells by allosensitized cytotoxic t lymphocytes. Abstr. (1978) (0)
A Tribute to James N. Miller: Colleague−Friend− Mentor (2016) (0)
Cancer resistance via the downregulation of the tumor suppressors RKIP and PTEN expressions: therapeutic implications (2023) (0)
Breast and Prostate Cancer Transcriptional Repression of the Metastasis Suppressor RKIP in Polycomb Protein EZH 2 Regulates Tumor Invasion via the (2012) (0)
Differential Presence of Truncated Forms of Transcription Factor Yin Yang 1 (YY1) in Bone Marrow of Multiple Myeloma Patients. (2005) (0)
Preface: Fifth International Workshop on Nitric Oxide (NO) and Cancer: Pathological and Therapeutic Aspects (2017) (0)
Guest Editor: Benjamin Bonavida (2020) (0)
P38 MAPK expression and activation predicts failure of response to CHOP in patients with Diffuse Large B-Cell Lymphoma (2015) (0)
Benjamin Bonavida Bio (2020) (0)
Eulogy to Professor John L. Fahey: My Teacher, Collaborator, and Professional Counselor (2015) (0)
Abstract 4582: Regulation of Krüppel-Like Factor 4 (KLF4) expressions via Yin Yang 1 (YY1) in B Non-Hodgkin's Lymphomas (B-NHLs): KLF4 upregulation is associated with unfavorable overall survival in pediatric B-NHL (2012) (0)
New therapeutic modalities in breast cancer by targeting NK cell inhibitory and activating receptors (2021) (0)
CC102528: A Novel Histone Deacetylase Inhibitor in the Hydroxamate Family Demonstrates Potent Anti-Myeloma Activity. (2009) (0)
The role of YY1 in the pathogenesis of rheumatoid arthritis: A tale of cytokines, ncRNAs, and aberrant fibroblast-like synoviocytes (FLSs) (2021) (0)
Repeated low-dose Pba/PDt treatments stimulate cell growth of prostate cancer cells (2013) (0)
Immunosuppressive Mechanisms of Tumor Associated Macrophages (TAMS): Bioinformatic Analyzes and Targeting TAMs (2021) (0)
The role of ia and inappropriate h-2d antigens on sjl/j reticulum cell sarcomas in syngeneic proliferation and recognition. Abstr. (1980) (0)
Cytotoxic response of sjl mice to syngeneic reticulum cell sarcomas. Abstr. (1977) (0)
Correlation between overexpression of YY1 and downregulation of DR5 in prostate tumor arrays: novel mechanism of escape from immune surveillance (2007) (0)
HIF-1a Expression and Implication in the Resistance Regulation and Malignancy in Pediatric Lymphomas Non-Hodgkin’s Tissue Arrays (2008) (0)
Mechanism of Obatoclax (GX15-070; Bcl-2 Family Inhibitor)-Induced-Sensitization of B-NHL Cells to TRAIL-Mediated Apoptosis: Inhibition of the NF-κB Survival Pathway and the DR5 Transcription Repressor Yin Yang1 (YY1) (2008) (0)
Tribute in Memory of Peter Stambrook. (2022) (0)
Abstract 4330: Transcriptional regulation of gp170 by YY1 and prognostic significance in childhood acute lymphoblastic leukemia (ALL) (2012) (0)
Nitric oxide decreases the transcription repressor activity of Yin-Yang 1 (YY1) via S-nitrosylation: Role in the immunosensitization of tumor cells to apoptosis (2004) (0)
The role of YY1 in drug resistant cancer: Involvement of the YY1/PTEN/PP2A/H2Ax/Rad51 axis (2021) (0)
Induction of RKIP and Inhibition of the Transcription Repressor YY1 in B-NHL by the Novel Proteasome Inhibitor NPI-0052 and Sensitization to TRAIL-Induced Apoptosis. (2006) (0)
Mechanism of chemosensitization of drug-resistant MM cell lines by anit- IgG3-avidin fusion protein targeting the transferrin receptor: inhibition of the Akt pathway and downregulation of XIAP and Bcl-xL (2007) (0)
The Pivotal Role of Yin Yang 1 (YY1) Inhibition (and downstream Bcl-2/Bclxl) by Galiximab (anti-CD80 mAb) In the Reversal of Resistance of B-NHL Cells to Chemotherapy (2010) (0)
EFFECT OF UVR AND MEMBRANE FLUIDITY ON NK CYTOTOXIC ACTIVITY1 (1985) (0)
Blocking TRAF6 Function Domain by TRAF6 Dominant Negative (TRAF6dn) for Inhibition of Multiple Myeloma Cell Proliferative and Increase of Apoptosis through Regulation of NF-κB and JNK Pathways. (2006) (0)
Unresponsiveness to CHOP Is Associated with Activation of the p38 MAPK Pathway in Patients with DLBCL (2011) (0)
The anti-CD20 Mab R603 induces PTEN and RKIP expression in B-NHL cells: role in inhibition of constitutively activated Akt and NF-κB survival anti-apoptotic pathways (2010) (0)
Identification of regulatory crosstalks between RKIP and BRCA1 tumor suppressors in healthy tissues and cancer (breast and ovarian): Therapeutic implications (2020) (0)
Aims and scope of series “Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy” (2022) (0)
Pleiotrophin Is Highly Produced by Myeloma and Breast Cancer and Transdifferentiates Human Monocytes into Endothelial Cells That Are Incorporated into Tumoral Blood Vessels. (2006) (0)
In vivo role of lymphocyte dependent antibody in mediating tumor allograft rejection. Abstr. (1973) (0)
B205 Efficacy of CEP-18770 on Myeloma Growth (2009) (0)
Natural Killer Cytotoxic Factor (Nkcf) as Mediator in the Lytic Pathway of Nk Cell Mediated Cytotoxicity (2018) (0)
Molecular mechanisms in cell mediated cyto toxicity inhibition by xenogeneic anti thymus derived cell sera of h 2 restricted and allo immune cyto toxic thymus derived lymphocyte mediated lysis (1980) (0)
Preface: Eli Sercarz Memorial Issue, Part III (2020) (0)
C14. NO-mediated chemosensitization of metastatic colon cancer in vivo: induction by NO of RKIP and AIF expression (2007) (0)
Rituximab-mediated inhibition of the Akt pathway and upregulation of PTEN expression in Ramos B-NHL leading to chemosensitization to drug-induced apoptosis (2006) (0)
Preface: Gamma-Delta T Cells in Inflammation Part 1. (2022) (0)
ELEVATION OF SERUM SOLUBLE CD27 LEVELS IN AIDS AND AIDS-ASSOCIATED LYMPHOMA: 121 (1997) (0)
Role of Natural Killer Cytotoxic Factors in Natural Killer Cell-Mediated Cytotoxicity1 (1986) (0)
Defective Natural Killer Cells in Melanoma: Role of NKG2D in Pathogenesis and Immunotherapy. (2021) (0)
Rituximab Inhibits the PI3K/Akt Survival Pathway In B-NHL Cells Via Induction of the PTEN Tumor Suppressor: Pivotal Roles of the Inhibition of the PTEN Repressors Snail and YY1 (2010) (0)
Natural Killer Cells in HIV Infection and Role in the Pathogenesis of AIDS (2001) (0)
PK11195, a Ligand of the Peripheral Benzodiazepine Receptor, Inhibits Myeloma Cell Growth In Vitro and Chemosensitizes Myeloma Cells In Vivo in SCID-hu Models of Human Multiple Myeloma. (2006) (0)
Preface: Circadian Rhythm and Oncogenesis Part 1 (2021) (0)
Abstract 2242: Correlation between the overexpression of the metastasis-inducer transcription factors Snail and Yin Yang 1 andBRAFmutations in a large panel of melanoma cell lines (2010) (0)
Physical, Chemical and Biological Properties of Stable Water (IETM) Clusters (1998) (0)
Chemosensitization of CDDP-Resistant Multiple Myeloma Cell Lines Following Treatment with Anti-TfR IgG3-Av. (2005) (0)
Overexpression and Preferential Nuclear Translocation of the Transcription Factor Yin Yang 1 (YY1) in Human Bone Marrow-Derived Multiple Myeloma. (2005) (0)
Induction of RKIP Expression by Anticancer Therapeutic Antibodies and Its Role in the Reversal of Chemo- and Immunoresistance (2011) (0)
Both NK sensitive and resistant mycoplasma free cell lines stimulate release of NKCF. (1985) (0)
Tumor Cell Resistance to Apoptosis by Infi ltrating Cytotoxic Lymphocytes (2008) (0)
CD4+ T LYMPHOCYTES ARE NECESSARY FOR DEVELOPMENT OF CARDIAC ALLOGRAFT VASCULOPATHY (1999) (0)
Inhibition of Multiple Myeloma Cell Proliferation and Increase of Apoptosis through Regulation of the NF-κB and JNK Pathways by Silencing TRAF6 C-Domain mRNA. (2004) (0)
Upregulation of KLF4 Expression in Pediatric B-NHL Lymphomas and Its Association with Low EFS and Poor Survival Following Treatment with Chemotherapy (2011) (0)
Binding, Receptor Characterization and Expression, and Intracellular Events (1990) (0)
Benjamin Bonavida, PhD (2019) (0)
CONCANAVALIN A INDUCED TRIGGERING OF ALLOSENSITIZED MEMORY LYMPHOCYTES INTO SECONDARY CYTOTOXIC LYMPHOCYTES (1977) (0)
COMMENTARY: Molecular and Biochemical Mechanisms of Photodynamic Therapy Anti-Tumor Effects (2011) (0)
Regulation of Chemoresistance and Immune Resistance of B-NHL Cell Lines by Overexpression of YY1 and Bcl-xL, Respectively: Reversal of Resistance by Rituximab. (2005) (0)
Abstract 1466: The NO donor DETANONOate inhibits the EMT phenotype in human metastatic prostate carcinoma cell lines: pivotal roles of inhibition of NF-κB and Snail activities and induction of RKIP (2010) (0)
Immunomodulation, Immunorestoration, Stress, and Disease (2020) (0)
Cooperation Between the CD20 Receptor and hIFN-Alpha Receptor in Overriding the Blocked CD20 Cell-Signaling in Rituximab-Resistant B-NHL By the Fusion Protein Anti-CD20-hIFN-Alpha (2015) (0)
Wnt/β-Catenin Signaling Is Essential for the Transdifferentiation of Monocytes into Endothelial Cells by mCSF and Pleiotrophin. (2007) (0)
Pivotal Role of Nitric Oxide (NO) Induction by Photodynamic Therapy in Tumor Cells: Modification of the NF-κB/Snail/RKIP Survival/Anti-Apoptotic Loop (2011) (0)
Abstract 3622: An antibody-based multifaceted approach targeting the human transferrin receptor for the treatment of multiple myeloma (2011) (0)
Aims and Scope for Series “Sensitizing Agents for Cancer Resistant to Cell Mediated Immunotherapy” (2020) (0)
Using the. casei in immunostimulatory compositions (2000) (0)
Zoledronic acid inhibits the earliest stages of vasculogenesis: blockage of the transdifferentiation of monocytes into endothelial cells induced by pleiotrophin and mCSF (2007) (0)
B206 Characterization of Cancer Stem Cells in Multiple Myeloma (2009) (0)
Peripheral Blood Cells from Multiple Myeloma Patients Show Increased Osteoclast and Decreased Osteoblast Gene Expression. (2005) (0)
The Overexpression of Inactive Phosphorylated Raf-1 Kinase Inhibitory Protein (RKIP) in Multiple Myeloma (MM) Regulates the Resistance to Bortezomib-Induced Cytotoxicity: Reversal of Resistance by the PKC Inhibitor Bisindolylmalemide (2011) (0)
Arsenic Trioxide Affects Early Stage Angiogenesis through Inhibition of CD14 Monocyte Transdifferentiation into Endothelial Cells Induced by Pleiotrophin and mCSF. (2006) (0)
Altered self antigens on reticulum cell sarcoma of sjl/j mice: role in mixed leukocyte tumor interaction (mlti). Abstr. (1980) (0)
C15. Therapeutic preclinical application of NO donor (e.g. DETANONOate) and CDDP in prostate tumor xenograft regression: molecular mechanism of synergy achieved in apoptosis (2007) (0)
Abstract B199: Transcriptional regulation of KLF4 by Yin Yang 1 (YY1) in pediatric B-NHL and clinical significance. (2013) (0)
Pha dependent immune rejection of syngeneic tumors. Abstr. (1976) (0)
Lysis of natural killer-sensitive and -resistant tumor cells by natural killer cytotoxic factors (NKCF)-containing liposomes. (1987) (0)
Galiximab (anti-CD80 mAb)-Induced Cell Triggering Results in the Inhibition of Constitutive NF-Kb Activity in Raji: Contrasting Roles of Snail and RKIP in the Regulation of Drug/Immune Resistance (2008) (0)
Low toxicity of inhaled interferon-gamma in four patients with lung metastasis from renal cell carcinoma. (1997) (0)
Zoledronic Acid Suppresses Vasculogenesis: A New Effect of Bisphosphonates. (2007) (0)
Comprar Nitric Oxide (NO) and Cancer | Bonavida, Benjamin | 9781441914316 | Springer (2010) (0)
Abstract #2725: Reduced expression of Raf-1 kinase inhibitor protein (RKIP) in human lung tumors: Prognostic significance (2009) (0)
Identification of the Alternating Oncogenic and Tumor-Suppressor Activities of Kruppel-Like Factor 4 in Various Human Cancers (2016) (0)
In Memoriam: Remembering Natale D'Alessandro's Friendship, Collaborations, and Career Research Mechanisms on Drug Resistance in Cancer (2020) (0)
Yin Yang 1 (YY1) Regulates The Transcription Of The Gene Krüppel-Like Factor 4 (KLF4) In Pediatric Burkitt Lymphoma: Clinical Implications (2013) (0)
Preface: Cancer and Stem Cells (2019) (0)
Abstract 2422: The trimeric engineered fusion protein with CD154 peptide mimetic (OmpC-CD154p), induced apoptotic signaling in B-NHL cell lines mediated by caspase 3 and caspase 8 activation (2010) (0)
Immunogenicity of tumor cells modified by trinitrobenzene suflonic acid (TNBS). (1976) (0)
Regulation of TRAIL-Medicated Apoptosis in Prostate Cancer by Overexpression of XIAP (2006) (0)
Frequency of thymus-dependent plaque-forming units: direct estimation by a modified plaque assay. (1977) (0)
The Role of Iron in the Cytotoxicity Induced in Hematopoietic Malignant Cell Lines by an Anti-Transferrin Receptor IgG3-Avidin Fusion Protein and Gambogic Acid. (2007) (0)
Preface: International Conference of Water and Health (2012) (0)
SUPPRESSOR CELLS WORKSHOP SUMMARY (1979) (0)
Galiximab Sensitizes Malignant Human B Cell Lines to Apoptosis by Chemotherapeutic Drugs. (2007) (0)
Antibody forming cells with specificity for autologous tissue antigens following lipopolysaccharide mitogenic stimulation in vitro. Abstr. (1976) (0)
of them all” for myelodysplastic syndromes (2007) (0)
Pleiotrophin is a key switch of human monocytes and bone marrow stem cells into endotherlial-like cells for angiogenesis in tumor growth (2005) (0)
Crosstalks between Yin-Yang 1 (YY1) and autophagy in cancer (2020) (0)
YY1-mediated regulation of type 2 diabetes via insulin (2021) (0)
Host-RCS Tumor Interactions in SJL/J Mice (1987) (0)
Blockage of CGEN-928 Expression Down-Regulates AKT Signaling Pathway and Inhibits Multiple Myeloma (MM) Cell Proliferation (2011) (0)
YY1 is involved in the pathogenesis and malignant properties of human triple-negative breast cancer (TNBC) (2021) (0)
Pleitrophin Is Highly Expressed by Myeloma Cells, Elevated in the Serum of Myeloma Patients, and Is a New Autocrine Growth Factor for This B Cell Malignancy. (2004) (0)
Yin Yang 1 is associated with cancer stem cell transcription factors (SOX2, OCT4, BMI1) and clinical implication (2016) (0)
Preface: Eli Sercarz Memorial Issue, Part I (2020) (0)
Abstract 766: Galiximab disrupts the dysregulated NF-κB/YY1/Snail/BclXLcircuit that regulates the resistance of B-NHL cell lines: Sensitization to chemo-immunotherapeutic drugs (2012) (0)
Actinomycin D-mediated sensitization of AIDS-Kaposi's sarcoma cells to Fas-mediated apoptosis: involvement of the mitochondrion-dependent pathway. (2002) (0)
Inhibition of the Akt Pathway in MM Cell Lines by the Anti-TfR-IgG3-Avidin Fusion Protein (Anti-TfR-IgG3-Av): Role in Chemosensitization to CDDP-Induced Apoptosis (2008) (0)
Photodynamic Therapy (PDT)-Mediated Inhibition of the Transcription Factor Yin Yang 1 (YY1) That Regulates Resistance In Lymphoma (2010) (0)
Preface Part 1: Immune Checkpoint Inhibitors and Autoimmunity. (2022) (0)
Identifying Crosstalk between Raf Kinase Inhibitor Protein and Systemic Lupus Erythematosus. (2019) (0)
Use of Lactobacillus casei in immune enhancing compositions (2001) (0)
Rituximab-Mediated Upregulation of PTEN Expression and Inhibition of Both the PI3K/AKT Pathway and Pleitrophin (PTN) Expression in B-NHL: Roles in Cell Growth Inhibition and Chemosensitization. (2006) (0)
Rituximab-Mediated Sensitization of B-NHL Cells Lines to TRAIL-Induced Apoptosis: Involvement of YY1 Suppression and DR5 Upregulation. (2006) (0)
The Anti-CD 20 Mab R603 Induces PTEN and RKIP Expression in B-NHL Cells: Role in Inhibition of Constitutively Activated Akt and NF-ΚB Survival Anti-Apoptotic Pathways. (2009) (0)
A new plaque assay to enumerate cytotoxic t lymphocytes (ctl). Abstr. (1976) (0)
Pleitrophin Alone Induces Transdifferentiation of Human Monocytes and Bone Marrow Stem Cells into Endothelial Cells. (2004) (0)
Separate membrane receptors on activated T cells determine the specificity of cell-mediated cytolysis (1976) (0)
Molecular interactions in t cell mediated cyto toxicity antigen nonspecific cyto toxicity following oxidative modification of membrane carbohydrates of cyto toxic t lymphocytes (1981) (0)
Preface: James N. Miller: A Journey Fighting Infectious Diseases (2016) (0)
Cross-Talk Cell Signaling between Anti-CD20 Antibodies and Nitric Oxide Donors. (2020) (0)
Abstract LB-305: The tyrosine kinase inhibitor bafetinib (INNO-406) inhibits osteoclast formation and bone resorption (2011) (0)
Pleiotrophin Is Highly Produced by Solid Tumors and Transdifferentiates Human Monocytes Into Endothelial Cells. (2009) (0)
Wasting, Endotoxin Shock, Vascular Effects, Inflammation, Infectious Diseases and Prevention of Side Effects (1990) (0)
Free-radicals dependent and independent pathways of cddp-mediated cytotoxicity and apoptosis in ovarian tumor-cell lines. (1995) (0)
IL‐10 TRANSGENE PREVENTS CARDIAC ALLOGRAFT VASCULOPATHY.: Abstract# 724 (2000) (0)
Inhibition of PC-3 prostate tumor cell growth in nude mice following treatment with combination of the NO donor DETANONoate and CDDP (2006) (0)
Multiple Myeloma-Specific Targeted Therapy: Use of the Tumor Specific Immunoglobulin Gene Sequence to Activate Drugs Only within Tumor Cells. (2009) (0)
The Role Of Nitric Oxide After Repeated Low Dose Photodynamic Treatments In Prostate Carcinoma Cells. (2015) (0)
Function of Effector T Cells (1985) (0)
An ADCC-Independent Mechanism of Rituximab-Mediated B-NHL Cells Depletion Via Sensitization to Cell Death through the Expression of TRAIL on NK Cells (2010) (0)
Regulation of prostate cancer sensitivity to apoptosis by CDDP by downregulation of XIAP and Bcl-xL expression via inhibition of constitutive NF-κB activity (2004) (0)
Higher TRAF6 and Fbxo 3 Expression Is With Progressive Multiple Myeloma and Blockage Of TRAF6 Inhibits Tumor Growth and Bone Resorption (2013) (0)
Eulogy for My Friend Michio Nishida (2014) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Benjamin Bonavida?

Benjamin Bonavida is affiliated with the following schools:

Benjamin Bonavida's Academic­Influence.com Rankings

Benjamin Bonavida's Degrees

Similar Degrees You Can Earn

Why Is Benjamin Bonavida Influential?

Benjamin Bonavida's Published Works

Published Works

What Schools Are Affiliated With Benjamin Bonavida?

Benjamin Bonavida's AcademicInfluence.com Rankings